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 1 General Introduction

9General introduction
Human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system 
of the human body. At the end of 2015 there were approximately 36,7 million people 
living with HIV worldwide with 2.1 million people becoming newly affected in 2015 [1]. 
In the Netherlands, 25,326 HIV-infected patients had ever been registered by the 
Stichting HIV Monitoring of whom 18,866 are in clinical care [2]. The majority of the 
HIV-infected patients in care, 11,616 (62%), are men who have sex with men (MSM). 
The rest of the population, men and women taken together, was infected by hetero- 
sexual contact (29%), intravenous drug use (2%), via blood contact (1%) or some other 
or unknown cause (6%).
 In the acute phase shortly after infection many patients go through an asymptomatic 
phase. Some patients may experience flu-like symptoms consisting of fever, swollen 
lymph nodes, sore throat, rash, weight loss, nausea and diarrhea. After the acute 
phase most patients feel fine for a long period of time. However, if left untreated, HIV 
progresses to Acquired Immune Deficiency Syndrome (AIDS) in a period of six 
months to 12 years [3]. A group of cells important for the immune system, called the 
CD4+ T cells, keeps declining in a person with AIDS leading to the development of 
opportunistic infections. These are infections that a healthy person would never get 
and are called ‘opportunistic’ because they take advantage of a weakened immune 
system. 
 Because HIV enters the brain, many persons with AIDS developed severe cognitive 
dysfunction (dementia) that was accompanied by motor and behavioral dysfunction. 
With the introduction of combination antiretroviral therapy in 1996, HIV changed from 
a fatal disease to a chronic illness. Symptoms of effectively treated patients, including 
dementia, vastly declined. However, in clinical practice patients still often report loss 
of concentration and memory problems. Studies so far have predominantly been 
focused on mixed patient groups, that is treated- and untreated and patients in 
variable stages of infection [4]. Furthermore, matched healthy control groups were 
often lacking. Moreover, comprehensive neuropsychological testing is not standard in 
many of the published studies. This thesis therefore focuses on cognitive performance, 
brain functioning and wellbeing in effectively treated HIV-infected patients in comparison 
to matched healthy control participants. 
HIV/AIDS infection and treatment
The main target cells of HIV are monocytes/macrophages and CD4+T-lymfocytes 
(CD4+ T cells) [5]. This type of white blood cells play an important role in the immune 
system. Macrophages increase inflammation and stimulate the immune system. 
They also have an anti-inflammatory role and can decrease immune reactions 
through the release of cytokines. CD4+T cells have multiple functions in the immune 
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system, ranging from activation of the cells of the innate immune system, B-lymphocytes, 
cytotoxic T cells, non-immune cells, and they play a critical role in the suppression of 
the immune reaction. Monocytes are being infected with HIV during their differentiation 
into macrophages, shortly after their exit from the bloodstream. Probably, macro - 
phages continue to produce virus after their terminal differentiation into tissue 
macrophages. Infected CD4+T cells are increasingly destroyed.  Destruction of these 
cells is initially compensated by an increased production of CD4+T cells, which 
causes a seemingly stable situation in the early stages of the disease. If left untreated, 
more and more CD4+ T cells are being destroyed, resulting in insufficient suppression 
of virus replication and a rapidly decreasing number of CD4+T cells. These events 
eventually lead to AIDS, the last stage of HIV. Primary HIV infection often causes 
non-specific symptoms consisting of fever, malaise, generalized lymphadenopathy, 
pharyngitis, diarrhea and rash. At this stage, plasma HIV RNA levels are usually high, 
which increases the risk of transmitting the infection. After the first stage of infection, 
HIV progresses to a chronic asymptomatic stage with a variable duration of six months 
to 12 years. A subset of patients gradually develop fatigue, subfebrile temperature, 
diarrhea and weight loss. Opportunistic infections and cancers start to develop when 
CD4+ T cell counts drop below 350 cells/mm3 and the immune system starts to 
collapse. A person is diagnosed with AIDS when the amount of CD4+ T cells in the 
blood is less than 200 cells per cubic millimeter (mm3) blood. In the absence of 
treatment, AIDS unavoidably leads to death. 
 The first class of antiretroviral therapy consisted of nucleoside analog reverse 
transcriptase inhibitors (NRTIs), like zidovudine (AZT) and lamivudine (3TC). NRTIs 
were initially almost exclusively used as monotherapy. Treatment with zidovudine 
appeared to be not very effective. Furthermore, AIDS patients quickly started to 
develop virus mutations that were resistant to zidovudine (AZT) and lamivudine (3TC). 
The introduction of highly active antiretroviral therapy (HAART) in 1996 has been a 
milestone in the history of HIV disease. HAART no longer consisted of just one drug, 
but combined three to four drugs from different classes: a combination of nucleoside 
analog reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse-transcriptase 
inhibitors (NNRTIs) like nevirapine and efavirenz, and protease inhibitors like ritonavir 
and indinavir. With some ‘triple therapies’ it became possible to longitudinally reduce 
the HIV RNA viral load in blood plasma and increase the amount of CD4+ T cells. 
Furthermore, treatment with HAARt, or cART (combination antiretroviral therapy) as 
it referred to nowadays, caused clinical improvement in patients, reducing the 
occurrence of opportunistic infections and significantly improving life expectancy. 
With the use of a combination of drugs, the development of treatment resistance has 
vastly declined. HIV-infected patients currently have a normal life expectancy if durable 
viral suppression with cART and a lifelong compliance can be achieved. 
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The HIV epidemic
The most affected region in the world is Sub-Saharan Africa, with 25.6 million people 
living with HIV in 2015, accounting for almost 70% of the global total HIV infections. It 
is estimated that currently only 54% of the people living with HIV know that they are 
infected [1]. Worldwide, 17 million HIV-infected persons were receiving antiretroviral 
therapy (ART) by end-2015. HIV can be transmitted via sexual contact, transfusion of 
blood and blood products, the use of contaminated needles, and vertical transmission. 
The risk of transmission via unprotected sex is around 0.5% [5].
 As mentioned in the first paragraph of the introduction, 24,313 HIV-infected patients 
have ever been registered by the Stichting HIV Monitoring (SHM) in the Netherlands. 
SHM is the Dutch national execute organization for the registration and monitoring of 
HIV-infected patients in follow-up in Dutch HIV Treatment Centres [2]. Of the registered 
patients, 18,866 patients were under clinical observation as of May 2016. Patients in 
clinical care were diagnosed with HIV on average 10.7 years ago and had a median 
age of 48. The median age has been increasing since 1996, which is mainly the result 
of the improved life expectancy of HIV-infected patients after the introduction of 
combination antiretroviral therapy (cART) in 1996. The great majority of patients in 
care in the Netherlands (95%) were being treated with cART. Due to earlier diagnosis 
and treatment CD4+ T cell count, both at diagnosis and start of cART, gradually have 
risen over time to a median of 370 and 420 cells/mm3, respectively, in 2015.
HIV and cognition
HIV and the brain
HIV infection causes disruptions in the junctions and weakens the blood brain barrier 
(BBB). The BBB separates the blood circulating through the body from the brain and 
is formed by endothelial cells, which are connected by tight junctions. The BBB 
allows the passage of nutrients, water, some gases, and lipid-soluble molecules by 
passive diffusion and selective transport of molecules that are critical to neural 
function, such as glucose and amino acids. On the other hand the BBB protects the 
brain by preventing the entry of potential neurotoxins. By disrupting the tight junctions, 
HIV weakens the BBB and facilitates the infiltration of infected white blood cells and 
other toxic substances into the brain. This increases permeability of the BBB which in 
turn facilitates viral entry, like neurotoxic viral proteins as Tat and gp 120,  into the 
central nervous system which may intensify neuroinflammation and thereby impair 
cognitive functioning [6]. 
1
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HIV-associated cognitive deficits in the pre-cART era and the first 
diagnostic guidelines 
Soon after the start of the AIDS epidemic it became clear that many HIV-infected 
patients developed progressive dementia that was frequently accompanied by motor 
and behavioral dysfunction. Snider et al. are generally seen as the first to systematically 
describe central nervous system (CNS) complications of AIDS in 50 patients [7]. 
Later, Navia et al. termed this clinical syndrome AIDS dementia complex (ADC) in 
1986 [8,9]. The researchers analyzed both clinical symptoms and neuropathological 
findings of 70 autopsied patients with AIDS. They found that nearly two-third of these 
patients developed ADC without focal or confounding metabolic disorders. Clinical 
symptoms of ADC were described in three areas: cognition, motor function and behavior. 
Cognitive impairment was characterized by memory deficits, loss of concentration and 
mental slowness. The motor problems consisted of loss of balance, motor coordination 
and tremor. Behavioral changes were predominated by apathy and social withdrawal. 
In the most advanced stage of AIDS, patients developed severe dementia and 
showed symptoms of mutism, incontinence, paraplegia, and sometimes myoclonus. 
Cases in these early studies often showed sudden acceleration of dementia and 
opportunistic infections [e.g. 8], which made it difficult to draw direct conclusions 
about the relation between HIV infection and cognitive impairment. This changed in 
1987, when Grant et al. published the first comprehensive study of HIV-related 
cognitive deficits, showing evidence of objective neurocognitive impairment across 
all stages of HIV disease and in multiple cognitive domains, including abstract 
reasoning, learning, and information processing speed [10]. Several years later, the 
AIDS Task Force of the American Academy of Neurology (AAN) defined diagnostic 
guidelines for classifying neurologic manifestations of HIV-infection. These criteria 
consisted of two levels: HIV-associated dementia (HAD) and minor cognitive motor 
disorder (MCMD) [11]. The criteria for HAD were 1) an acquired deficit in at least two 
cognitive (non-motor) domains causing impairment in work or activities of daily living 
(ADLs) and 2) an abnormality in motor function or specified neuropsychiatric or 
psychosocial functions (e.g., motivation, emotional control, social behavior). MCMD 
described a less severe condition for which the criteria were a history of impaired 
cognitive or behavioral function in at least two areas (e.g., impaired attention or 
memory, mental slowing, personality change, irritability). These abnormalities caused 
mild impairment in work or ADLs and did not meet the criteria for HAD. 
HIV-associated neurocognitive disorders: HAND
In 2007 Antinori et al. described several issues with the AAN criteria that restricted 
their applicability [12]. The AAN criteria did not define the number of cognitive domains 
that should be examined for diagnosis and the degree of neurocognitive impairment 
was not fully specified. Also, there seemed to be overlap between the criteria for HAD 
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with mild functional impairment and MCMD and the criteria did not define mild forms 
of reliably identifiable cognitive difficulties which had not yet developed to marked 
problems in everyday functioning. To address these points of concern, the HIV Neu-
robehavioral Research Center (HNRC) at the University of California, San Diego 
proposed new guidelines to classify HIV-related neurocognitive complications that 
have been widely adopted. This classification, often referred to as the ‘Frascati criteria’ 
provides a tool to classify and identify HIV-associated neurocognitive disorders 
(HAND) and distinguishes three conditions: asymptomatic neurocognive impairment 
(ANI), HIV-associated mild neurocognitive disorder (MND), and HIV-associated 
dementia (HAD) (see table 1). ANI requires mild impairment (at least 1 standard 
deviation (SD) below the mean of demographically adjusted normative scores) 
without interference with everyday functioning. MND is defined as mild cognitive 
impairment (at least 1 SD below the normative mean) with mild interference in daily 
functioning. The most severe form of HAND, HAD, requires severe cognitive impairment 
(at least 2 SD below the mean) accompanied by marked interference in everyday 
functioning. Cognitive impairment in all three forms of HAND should be present in at 
least two cognitive domains and cannot be explained by a delirium or other 
comorbidities. Furthermore, classification of HAND must be determined by assessing 
at least five cognitive domains known to be affected by HIV (e.g., executive functioning, 
attention/working memory, language, speed of information processing, motor 
1
Table 1  The Frascati criteria to classify HAND
HAND diagnosis Criteria
HAD: HIV-associated dementia · Severe cognitive impairment (at least  
2 standard deviation below the mean in 
two cognitive domains)
· The cognitive impairment is 
accompanied with marked interference in 
everyday functioning
MND: Mild neurocognitive disorder · Mild cognitive impairment (at least  
1 standard deviation below the mean in 
two cognitive domains)
· The cognitive impairment produces mild 
interference in daily functioning
ANI: Asymptomatic neurocognitive impairment · Mild cognitive impairment (at least  
1 standard deviation below the mean in 
two cognitive domains)
· The cognitive impairment does not 
interfere with day-to-day functioning
14
functioning, memory). Cognitive impairment requires that at least one of the assessed 
cognitive domains be primarily cognitive in nature. This means that impairment that 
is limited to motor functioning would not qualify. Also, these cognitive domains should 
preferably be evaluated using neuropsychological tests that are interpreted with 
published norms that are demographically adjusted (for age, education and sex). 
However, if neuropsychological testing is not available, the criteria allow for use of 
standardized mental status examinations (using demographically appropriate normative 
cutoff scores). 
Cognition in the cART era
Since the availability of cART, life expectancy has increased dramatically, and within 
2 years of the widespread availability of cART, the number of HIV-related deaths in 
Europe were less than a fifth of those before HAART [13,14]. Also many studies report 
that the prevalence of severe cognitive impairment has declined vastly [15-19]. In the 
past few decades, many studies showed that milder forms of HAND, (i.e., ANI and 
MND) are present in virologically stable HIV-infected patients [4,19-21]. Cognitive 
decrements have been demonstrated in many different cognitive domains. However, 
deficits in speed of information processing, attention, memory, particularly learning 
and retrieval of information and executive functioning, are most prominent [22-24]. 
Estimates of the prevalence of cognitive impairment in the cART era vary from 18 to 
69% of HIV-infected patients worldwide [4,21,25-27]. 
Neuropsychological assessment
Numerous neuropsychological tests are available to evaluate individual cognitive 
domains (for comprehensive overviews see Lezak et al. 2012 [28]; Bouma et al. 2012 
[29]). Because neurocognitive deficits are mostly mild in the cART era and different 
patients may show impairments in a variety of cognitive domains, assessment of 
cognitive functioning requires testing of multiple cognitive functions covering all 
cognitive domains. Many large HIV cohort studies use extensive neuropsychological 
test batteries that they have developed themselves. However, as these batteries are 
extensive, they are also time-consuming and can only be reliably administered and 
interpreted by trained clinical neuropsychologists. Therefore, there is a need among 
both clinicians and researchers for short screening tools that reliably assess cognitive 
functioning. The HIV Dementia Scale (HDS), and later the International HIV Dementia 
Scale (IHDS) were developed to screen for HAD, the most severe form of HAND [30]. 
The HDS contains items assessing memory, attention, psychomotor speed and vi-
suoconstruction and has been shown to be adequate in detecting severe cognitive 
impairment (see Box 1). However, the HDS is highly insensitive for milder forms of 
15
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cognitive impairment [31-34]. Another instrument that may be valid for screening for 
HIV-related cognitive impairment is the Montreal Cognitive Assessment (MoCA) [35]. 
This tool evaluates eight cognitive domains, including executive functioning, memory, 
attention and language. Several studies show that the MoCA is sensitive to detect 
milder forms of cognitive impairment [36-41]. Other cognitive screening tools that 
have been used to assess HIV-related cognitive deficits are the Mini Mental Sate 
Examination (MMSE), the CogState battery, and the Computerised Assessment of 
Mild Cognitive Impairment (CAMCI) [32]. At the time, few studies had investigated the 
validity of the MoCA in HIV-infected patients. Also, many studies investigating the 
validity of the HDS used only the Frascati criteria to classify cognitive impairment.
Box 1  The HIV Dementia Scale
The HIV Dementia Scale is a short cognitive screening tool developed to screen for HIV-
associated dementia (HAD) [30]. This test consists of four items measuring memory, 
attention, psychomotor speed and visuoconstruction and takes approximately 5 to 10 
minutes to administer. The memory item consists of four words that the patient has to repeat. 
After two items the patient is asked to recall the four words. Attention is measured with an 
antisaccadic eye movement task of 20 trials in which the patient has to look to the pair of 
fingers the instructor is not moving. An error is recorded when the patient looks towards 
the fingers that are moving. To measure psychomotor speed, the patient has to write the 
alphabet in uppercase letters horizontally across the page as fast as he/she can. In the last 
item the patient is asked to draw a cube , to measure visuoconstruction. Subsequently a 
total score is calculated by summing scores of the four items, with a maximum score of 16. 
A score <11 indicates cognitive impairment.
Neuroimaging
In addition to neuropsychological tests and cognitive screening instruments, 
neuroimaging is a widely used diagnostic tool to investigate the pathogenesis of HIV 
infections of the CNS in relation to cognitive functioning. Cerebral atrophy and white 
matter abnormalities are the two most common and robust neuroimaging findings in 
HIV-infected patients [9,42-48]. Volume reductions of the amygdala, caudate nucleus, 
thalamus and hippocampus and cingulated cortex have been reported [49,50]. 
Furthermore, resting-state functional magnetic resonance imaging (rs-fMRI) is a 
technique that can be used to evaluate regional brain interactions that occur when a 
subject is not performing an explicit task. Resting neural activity can be observed 
through changes in blood flow in the brain which is termed blood-oxygen-level 
dependent (BOLD) signal and can be measured using fMRI. The brain shows activity 
1
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even in the absence of an externally driven task, therefore spontaneous fluctuations 
in BOLD signal in the brain are present. Rs-fMRI quantifies the temporal correlation in 
spontaneous BOLD fluctuations [51]. Abnormalities have been reported in the default 
mode network (DMN), a network associated with internally directed and self-regulated 
thought, like mind-wandering and mental simulation and the executive control 
network. This network is active when a person performs cognitive tasks that require 
externally directed attention, such as working memory, response inhibition and set 
switching  [51-54]. The degree of brain abnormalities has been associated with HIV 
disease stages in the pre-cART era [45]. While abnormalities have been demonstrated, 
it is unclear how and to what extent they are related to cognitive decline over time. 
For instance, no increase in atrophy has been described in a 7-year follow-up study 
in the cART era with patients in the early stages of infection [55]. Some studies showed 
a correlation between the degree of atrophy and impaired cognitive performance 
[56-58],  but others did not found a relation between HIV infection and brain volume 
reductions [49]. 
Psychological wellbeing
As HIV infection is a chronic illness that is often surrounded by stigma, psychological 
wellbeing is an important topic in studies on neurocognition in HIV infected patients. 
Cognitive complaints and impairments can affect psychological wellbeing and may 
interfere with work, social interactions and daily functioning [59-61]. Several studies 
reported associations between psychological wellbeing and cognitive performance 
[26,60,62]. Also, medication characteristics are reported to have an effect on wellbeing. 
For example, efavirenz is often related to neuropsychiatric symptoms like insomnia, 
dizziness, nightmares, problems in concentration and depression [63-65]. 
Thesis Outline
This thesis focuses on neurocognition in effectively treated HIV-infected patients on 
cART treatment, in short, the Art-NeCo study. 
 As many patients report memory problems and loss of concentration and large 
Dutch HIV cohort studies that focus on cognitive functioning, neuroimaging and 
wellbeing were lacking, the main aim was to investigate cognitive functioning in a 
group of well-treated HIV-infected patients on long-term cART. Also, published 
studies often lacked a well-matched HIV-negative control group and symptom validity 
testing. The research in this dissertations therefore started with a pilot study to assess 
the nature and extent of deficits in cognitive performance in relation to psychological 
17
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wellbeing in Dutch HIV-infected patients. In chapter 2 cognitive performance and 
psychological wellbeing were examined in a HIV-infected patient group in comparison 
to a matched HIV-negative control group, while taking symptom validity into account. 
In chapter 3 the pilot study was extended with a larger group of HIV-infected patients 
and matched HIV-negative control participants. Also, magnetic resonance examinations 
were included. The aim was to integrate results from extensive neuropsychological 
testing, subjective wellbeing reports and magnetic resonance imaging (MRI) volumetric 
measures.
 Chapter 4 focuses on cognitive decline over a one-year period of time. Test-retest 
scores for a comprehensive neuropsychological assessment were examined. This 
study also related HIV disease and treatment characteristics, psychological and 
baseline variables with cognitive decline. 
Since neuropsychological assessment may be time consuming and requires trained 
professionals to administer, several brief screening tools have been developed over 
the years. The validity of two short cognitive screening tools, the Montreal Cognitive 
Assessment (MoCA) and the HIV Dementia Scale (HDS),  in detecting cognitive 
impairment is described in chapter 5. 
 Next to volumetric measures, resting-state functional connectivity was examined 
in subcortical structures of the brain. Specifically, a study that investigated disruptions 
in the basal ganglia, hippocampus, amygdala, and thalamus is presented in chapter 6. 
Finally, in chapter 7, a general discussion of the reported studies is presented. The 
findings of the studies described in this thesis are summarized and discussed. 
Furthermore clinical relevance and implications for future research are highlighted. 
1
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Abstract
The objective of this study was to examine and relate both cognitive functioning and 
psychological wellbeing in Dutch HIV-1 infected patients (n=30) in comparison with 
a matched healthy control group (n=30), taking symptom validity into account.
 Significant differences in performance between patients and controls were found 
in the domain Working memory (p =0.036), but not in the other cognitive domains. 
There was a significant difference on all dimensions of the psychological wellbeing 
scale, measured with the SCL-90-R (p-values between 0.002 and 0.023), except for 
agoraphobia, cognitive performance difficulty and sleep disturbances. No correlations 
were found between the performance on the Working memory domain and wellbeing.
 Future research should focus on unravelling the underlying mechanisms of neuro- 
cognitive dysfunction further using neuropsychological tests, including a symptom 
validity test in combination with neuroimaging techniques in larger samples.
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Introduction
Combination antiretroviral therapies (cART) has improved the course of HIV infection 
dramatically. Nevertheless, several studies have shown that 30-60% of these patients 
develop at least mild cognitive impairments [1]. Deficits in Memory, Psychomotor 
speed, Attention and Executive functioning are most prominent [2]. Cognitive deficits, 
even in mild or moderate forms, may potentially hamper everyday activities and may 
cause problems in achieving life goals, which in turn might result in diminished 
psychological wellbeing and quality of life [3,4]. Psychiatric symptoms are present in 
almost 50% of HIV-1 infected individuals, of which depressive symptoms, anxiety, 
mania, psychosis and substance abuse are the most common [5].
 Several studies report a relation between psychological wellbeing and cognitive 
functioning [6,7]. Carter et al. (2003) examined the relation between cognitive 
impairments and psychological complaints in HIV-1 infected patients, using structural 
equation modelling [8]. Here, they found that increased cognitive complaints were 
associated with worse neuropsychological performance and that depressed mood 
and physical symptoms also affected the self-reported cognitive complaints. 
However, other results did not reveal correlations between depressive symptoms and 
cognitive functioning [9]. 
 Very few studies on cognitive functioning in HIV-1 infected patients have taken 
symptom validity into account. Woods et al. (2003) pointed out that it is possible that 
a small subset of HIV-1 infected patients might feign or exaggerate their neuropsy-
chological deficits in order to obtain monetary compensation and/or service benefits 
[10]. The detection of invalid neuropsychological test performance due to insufficient 
mental effort in possible disability or compensation-seeking individuals is important 
in both clinical and research settings. Symptom validity tests are useful tools in the 
detection of suboptimal mental effort in that they are designed to be passable for all 
but the most severely impaired patients, given that the participant has provided 
adequate effort in the test. Furthermore, a substantial amount of studies on cognitive 
functioning and wellbeing lack a non-HIV-1 infected control group.
 Considering the lack of consensus about the existence of a relation between 
cognition and wellbeing, the present study aimed to assess the nature and extent of 
changes in cognitive performance and to explore the relationship with psychological 
wellbeing in a randomly selected sample of HIV-1 infected patients in comparison 
with a matched HIV-negative control group. A symptom validity test is included to 
take suboptimal mental effort into account. 
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Methods
Participants
Thirty HIV-1 infected patients and 30 controls were included between March 16th 
2009 and December 19th 2011. Consecutive patients were recruited through their 
treating physicians via the outpatient clinic for infectious diseases at the department 
of General Internal Medicine in the Radboud University Nijmegen Medical Centre if 
they met the following inclusion criteria: age between 18 and 70 years, fluent in the 
Dutch language, no current drug or alcohol addiction, and no history of psychiatric or 
neurological disorder (unrelated to HIV-1 infection in the patients). Inclusion criteria for 
the patients were an HIV-1 infection and absence of active opportunistic infections, 
pregnancy, malignancy, and neurosyphilis. Patients were selected regardless of the 
presence of signs or symptoms of suspected cognitive impairment or subjective 
cognitive complaints. Controls were recruited among spouses and acquaintances of 
the HIV-1 infected patients and the network of the researchers and were matched for 
age, sex and education level. For measuring the amount of drug and alcohol use, a 
subscale of the European Addiction Severity Index (EuropASI) was administered [11.] 
Medical ethical approval was obtained for this study and written informed consent 
was obtained from all participants.
Neuropsychological Assessment
Participants completed an extensive neuropsychological test battery measuring six 
major cognitive domains. Abstract reasoning was assessed by Raven Advanced 
Progressive Matrices (12-item short form) [12]. Memory was divided into two 
subdomains, Working memory and Episodic memory. Working memory was assessed 
by the Letter-Number Sequencing of the Wechsler Adult Intelligence Scale, third 
edition (WAIS-III) [13]. Episodic memory was assessed verbally and nonverbally with 
the Dutch version of the Rey Auditory Verbal Learning Task and the Location Learning 
Task – Revised respectively [14,15]. Both Episodic memory tasks consisted of 
immediate memory (total score on trials 1-5) and delayed recall. The domain 
Psychomotor speed included Digit symbol Substitution subtest from the WAIS-III and 
the Grooved Pegboard Test (administered for the dominant and non-dominant hand) 
[13,16]. Visuoconstruction was measured with the copy trial of the Rey-Osterrieth 
Complex Figure Test [17]. Executive functioning consisted of four subdomains: 
Concept shifting, Response generation, Planning and Response inhibition. Concept 
shifting was measured with de Brixton Spatial Anticipation Test [18]. Response 
generation was assessed with a letter fluency tasks (K-O-M; 1 minute per letter) [19]. 
Planning was assessed with the Zoo Map test from the Behavioural Assessment of 
the Dysexecutive Syndrome (BADS) [20]. Response inhibition was assessed by the 
Stroop Color-Word Test [21]. Here, the Stroop interference score was computed, 
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using the following formula: (time needed for card III - time needed for card II) / time 
needed for card II [22]. Finally, Attention was measured with the 2.0 and 1.6 Inter 
stimulus interval (ISI) trials of the Paced Auditory Serial Addition Test (PASAT) 
(60-items per ISI) [23]. 
 Tests were chosen to be sensitive to small or moderate differences in ability and 
were administered by trained neuropsychologists. The allocation of tests to the 
domains was made a priori, according to standard neuropsychological practice and 
cognitive theory [24]. The assessment took 90-120 minutes and all tests were 
administered in a fixed order. 
 Psychological wellbeing was assessed with the 90-item revised Dutch version of 
the Symptom Checklist (SCL-90-R) [25]. The SCL-90-R is a multidimensional self- 
report questionnaire designed to screen for a broad range of psychological problems 
by asking subjects to reflect on the previous seven days. The questionnaire contains 
90 items subdivided in eight symptom dimensions: agoraphobia, anxiety, depression, 
somatization, cognitive performance difficulty, interpersonal sensitivity, anger-hostility 
and sleep disturbance. Responses are given on a scale of 1 to 5 and a score for each 
of the dimensions is calculated, in addition to one global score: the Total score. 
Symptom validity was measured with the short version of the Amsterdam Short Term 
Memory Test (ASTM) (cut-off score < 85) [26]. Education level was recorded using 
seven categories in agreement with the Dutch educational system (1=less than 
primary school; 7=academic degree). Premorbid intellectual level was estimated with 
the Dutch version of the National Adult Reading Test [27].
 Clinical ratings of neuropsychological test performance were computed for each 
of the HIV-1 infected patients. Neuropsychological impairments were classified per 
cognitive domain using age- and education-adjusted normative data in patients and 
controls (i.e., using 1.65 SD below the normative mean as cut-off, reflecting the lowest 
5% of the normative population) [24,28]. Impairments had to be present in at least two 
domains for a participant to be classified as ‘cognitively impaired’. At least one of the 
ability deficits had to be outside the motor and sensory perceptual domain, in 
agreement with the updated nosology for HIV-associated neurocognitive disorders 
by Antinori et al. (2007) [29]. 
Statistical Analysis
To compare the different cognitive domains, raw test scores were transformed into 
z-scores. Positive test scores for the Location Learning Test, the Grooved Pegboard 
Test and the Stroop Color-Word Test were converted into negative z-scores and 
negative test scores, for these tests, into positive z-scores to make sure that higher 
scores indicated a better performance for all tests. Subsequently, domain scores 
were calculated by averaging the z-scores of the tests that contributed to the six 
cognitive domains. Between-group differences in cognitive functioning were examined 
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with a general linear model multivariate analysis of variance (MANOVA) with group as 
independent variable and the cognitive domains as dependent variables. General 
linear model univariate analyses of variance (ANOVA) were performed for between- 
group differences in the subscales of the SCL-90-R, with group as independent 
variable and each subscale as dependent variable. Effect sizes (partial eta-squared 
[ηp
2]) were computed for all analyses.
 In agreement with Woods et al. (2003), a performance below the cut-off of a 
symptom validity test is likely not the result of HIV-associated cognitive impairment 
and must therefore be regarded as an indication of underperformance [10]. 
Participants performing below this cut-off were removed from the statistical analyses.
Results
Table 1 shows the characteristics of the two groups. No significant differences were 
found in sex distribution (χ²(1)=0.111, p=0.739), level of education (U=433.5, 
Z=-0.255, p=0.799) and estimated IQ (t(58)=-1.715, p=0.092) between patients and 
controls, indicating that the groups were well matched on these variables. Five patients 
and one control performed below the cut-off indicative for underperformance on the 
ASTM. However, this differences between the groups was not statistically significant 
(χ²(1) =0.963, p=0.085). With respect to participants performing in the ‘impaired’ 
range (excluding all participants who performed suboptimally on the symptom 
validity test), 12% of the patients were classified as neuropsychologically impaired 
compared to 3.5% of the controls. MRI data were available for 26 of the patients and 
CSF viral load was obtained in 25 patients.
 Six of the participants scored below the cut-off (< 85) of the symptom validity 
test (ASTM), these participants were excluded from all further analyses. Scores on 
the cognitive domains and each individual test (mean z-scores ± standard deviation 
for the cognitive domains and raw test scores ± standard deviation for tests) of the 
two groups are shown in table 2. Overall, results of the MANOVA showed a significant 
difference between the groups on cognitive function (F(1,52)= 2.83, p=0.015, 
ηp
2=0.30). Subsequent analyses of the individual domains showed a significantly 
worse performance in the patients on the domain Working Memory compared to 
controls (F(1,52)=4.63, p=0.036, ηp
2=0.082). The patients performed statistically 
significantly better than controls on the domain Visuoconstruction (F1,52)=10.12, 
p=0.002, ηp
2=0.163). None of the other domains showed significant group differences 
(all F-values<1.64). 
 With respect to psychological wellbeing (table 3), significantly higher levels of 
complaints in patients were found on the subscales anxiety, depression, somatic 
complaints, interpersonal sensitivity, hostility and on the total score (p-values between 
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0.002 and 0.023). No significant difference between the groups was found on the 
subscales agoraphobia, cognitive performance difficulty and sleep disturbances. 
A correlational analysis was conducted taking all participants together (n=54) in order 
to establish whether or not psychological wellbeing was correlated with cognitive 
functioning for the impaired domain Working memory. None of the wellbeing 
subscales were significantly correlated with cognitive performance on the domain 
Working memory (Pearson’s r between -0.24 and -0.04). Furthermore, no difference 
was found with respect to the performance on Working memory between patients 
with a nadir CD4 <200 and patients with a nadir CD4 ≥200 (t(23)=0.85, p=0.402). 
Also, the lower performance on the domain Working memory remained significant 
when the untreated HIV-1 infected patients were excluded from the analysis 
(F(1,44)=6.93, p=0.012, ηp
2=0.14).
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Table 1  Participant characteristics.
Characteristics HIV-1 infected patients
(n=30)
Controls
(n=30)
Age in years (mean ±SD) 46.67 (10.67) 48.47 (9.90)
Sex (male:female) 25:5 24:6
Estimated IQ (mean ±SD) 96.37 (15.17) 102.13 (10.44)
Education level (mode, range) 6 (6) 5 (3)
Receiving cART (%) 73.3% -
CSF viral load* ≤ undetectable† (%) 56% -
CSF viral load* > undetectable† – 10.000 c/ml (%) 44% -
Nadir CD4 (median, IQR) 280 (115-360) -
Nadir CD4 <200 (%) 30%
Nadir CD4 ≥200 (%) 70%
MRI** White-matter abnormalities 19.2% -
MRI** Grey-matter abnormalities 7.7% -
Regular alcohol use†† 43.3% 93.3%
Regular cannabis use†† 20% 0%
Regular drug use†† other than cannabis 3.3% 0%
* In 25 patients HIV RNA viral load was measured in the cerebrospinal fluid. **In 26 patients MRI of the 
brain was made (T2- weighted MRI, 1.5 Tesla). †undetectable CSF = ≤20 c/ml; ††Regular use is use of 
a substance for three or more times a week.
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Table 2   Neuropsychological performance on the different cognitive domains 
and on each test for the HIV-1 infected patients and control group. 
Cognitive domains HIV-1 infected patients
(n=25)
Controls
(n=29)
Abstract reasoning 0.10 (± 0.83) -0.08 (± 1.14)
Raven Advanced Progressive Matrices  
(mean total score) 
9.20 (± 1.58) 8.86 (± 2.17
Working memory -0.31 (± 1.07)* 0.26 (± 0.87)
WAIS-III Letter-Number Sequencing  
(mean total score) 
9.80 (± 2.20) 10.97 (± 1.78)
Episodic memory -0.00 (±0.69) 0.00 (± 0.94)
Rey Auditory Verbal Learning Test  
(mean total score on trials 1-5)
39.16 (± 7.66) 40.69 (± 8.98)
Rey Auditory Verbal Learning Test  
(mean delayed recall score)
7.40 (± 2.80) 7.72 (± 3.60)
Location Learning Test-R  
(mean total score on trials 1-5)
23.36 (± 17.91) 22.38 (± 20.34)
Location Learning Test-R  
(mean delayed recall score)
1.48 (± 2.69) 2.72 (± 4.93)
Psychomotor speed 0.04 (± 0.85) -0.04 (± 0.68)
Grooved Pegboard Test dominant hand  
(mean score)
73.48 (± 13.01) 75.03 (± 9.30)
Grooved Pegboard Test non-dominant hand  
(mean score)
82.32 (± 19.42) 85.10 (± 15.09)
WAIS-III Digit Symbol substitution  
(mean score)
71.60 (± 17.18) 72.45 (± 14.53)
Visuocontruction 0.43 (± 0.57)* -0.37 (± 1.14)
Rey Complex Figure-copy (mean score) 35.58 (± 0.86) 34.36 (± 1.74)
Executive functioning -0.08 (± 0.50) 0.07 (± 0.38)
Brixton Spatial Anticipation Test (mean score) 39.88 (± 6.67) 40.55 (± 4.96)
Letter Fluency Test (mean trials K-O-M) 36.00 (± 10.99) 39.31 (± 8.92)
BADS Zoo Map Test (mean score condition 1-2) 12.24 (± 3.66) 11.72 (± 3.39)
Stroop Color Word Test (interference score) 0.64 (± 0.26) 0.57 (± 0.16)
Attention -0.04 (± 1.02) 0.04 (± 0.87)
Paced Auditory Serial Addition Test 2.0 ISI  
(mean score)
33.32 (± 13.46) 35.10 (± 11.18)
Paced Auditory Serial Addition Test 1.6 ISI  
(mean score)
30.68 (± 11.34) 30.83 (± 10.28)
Domain scores are presented as mean z-scores ± standard deviation. Negative z-values indicate worse 
performance. Test scores are presented as mean raw test scores ± standard deviation. *p<0.05.
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Discussion
The results of this study showed a worse performance on cognitive functioning in our 
sample of HIV-1 infected patients compared to uninfected controls when combining 
all tests in one overall analysis. This effect is mainly due to a worse performance of 
the patient group on Working memory, with a medium-to-large effect size [30]. This 
worse performance in patients compared to controls was also reflected in the clinical 
evaluation of the neuropsychological assessment, were 12% of the patients were 
classified as cognitively impaired compared to 3.5% of the controls. This finding is in 
line with previous results showing that deficits in Working memory are among the 
strongest predictors of cognitive complaints in HIV patients [31]. In contrast with 
several previous studies, no impairments in other cognitive domains were found in 
the present study [1,32]. A possible explanation for this discrepancy may be found in 
differences in disease stages or number of patients on cART treatment across 
studies. That is, the severity of the neuropsychological dysfunctions may be 
associated with the disease stage of HIV-1 [2]. Moreover, neuroimaging data of a 
subgroup of our sample demonstrated grey- and white-matter abnormalities in 
approximately 25% of the patients that may underlie the cognitive decrements that we 
observed.   
 Furthermore, our results showed that patients report more psychological complaints 
than controls. Specifically, they reported higher levels of anxiety, depressive symptoms, 
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Table 3   Mean scores on the different dimensions of the SCL-90-R for the HIV-1 
infected patients and controls. 
Dimension HIV-1 infected patients
(n=25)
Controls
(n=29)
P
Agoraphobia 7.92 (±1.38) 7.48 (±1.35)) 0.026
Anxiety 15.16 (± 4.81) 12.17 (±2.16) 0.004**
Depression 25.44 (± 7.58) 20.28 (± 3.87) 0.002**
Somatization 19.48 (±7.11) 15.69 (± 4.69) 0.023*
Cognitive Performance difficulty 16.36 (± 6.60) 14.10 (± 3.38) 0.113
Interpersonal sensitivity 25.68 (± 5.27) 21.93 (± 3.93) 0.004**
Anger-Hostility 8.12 (± 2.09) 6.79 (± 0.90) 0.003**
Sleep Disturbance 6.20 (± 3.01) 4.93 (± 2.63) 0.105
Total score 136.08 (± 30.68) 113.52 (± 18.55) 0.002**
Dimension scores are presented as mean scores ± standard deviation. *p<0.05; **p<0.01.
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somatic complaints, lowered self-esteem and heightened irritability. Interestingly, patients 
did not report higher levels of cognitive complaints. The finding that patients showed 
high levels of psychological complaints might be due to the chronic nature of HIV-1, as in 
chronic illness depression- and anxiety-related complaints are frequently reported [33]. 
While psychological complaints may affect cognitive functioning, we did not find any 
significant correlations between the dimensions of psychological wellbeing and 
Working memory [7]. This may indicate that psychological complaints do not fully 
explain the lower performance on Working memory in our sample of HIV-1 infected 
patients. 
 One of the strengths of the current study is that it is one of the few to examine 
cognitive functioning in HIV-1 infected patients that assessed symptom validity, which 
is important to be taken into account in HIV-1 infected patients [10]. In our study, 5 out 
of 30 HIV-1 infected patients obtained a score under the cut-off on the symptom 
validity test and 1 of the 30 controls performed below the cut-off. These participants 
were removed from the analyses. However, this difference on the symptom validity 
test between patients and controls was not statistically significant. In contrast, the 
slightly better performance of the patients on the domain visuoconstruction compared to 
controls has previously been linked to optimal mental effort during cognitive testing [34]. 
Another strength is that both cognitive performance and psychological wellbeing were 
compared with a matched healthy control group in a single study. Previous studies 
either lacked a matched control group or examined cognition or wellbeing in isolation. 
Next to a healthy control group, future studies could include controls with other 
chronic diseases to take non-HIV-specific emotional consequences into account. Also, 
studies in European samples of HIV-1 infected patients are scarce. A limitation of this 
study is that cART treatment may have influenced cognitive performance, partly due 
to differences in penetration into the CSF [35]. Another limitation was that data about 
viral load and MRI were not available for all patients, and that MRI abnormalities could 
not be quantitatively analysed using e.g. volumetry. Finally, in this study both treated 
and untreated patients participated, but the lower performance on Working memory 
remained significant when the untreated patients were excluded from analysis.
 In all, this cross-sectional pilot study showed decrements in cognitive functioning, 
specifically in Working memory even in a small, randomly selected, sample of HIV-1 
infected patients, as well as lower levels of psychological wellbeing. The findings of 
the current study indicate that future research should focus on unravelling the 
underlying mechanisms of neurocognitive dysfunction further, using neuropsycho-
logical tests, including a symptom validity test in combination with neuroimaging 
techniques and taking other aspects of quality of life into account than psychological 
wellbeing in larger samples. Finally, longitudinal studies examining the course and 
clinical significance of cognitive functioning in large cohorts of patients are warranted. 
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Abstract
The objective of the current study is to integrate results from extensive neuropsycho-
logical assessment, subjective wellbeing reports and structural neuroimaging findings 
in succesfully treated HIV-infected patients in comparison with a HIV-negative control 
group. Neuropsychological functioning and self-reported wellbeing were assessed in a 
group of 102 virologically suppressed HIV-infected patients on cART and 56 controls. 
Both groups underwent MR examinations and grey matter, white matter and sub- 
cortical volumes were determined. Brain Parenchymal Fraction (BPF) was calculated 
as an estimated measure of global brain atrophy. HIV-infected patients showed worse 
information processing speed (P=0.01) and motor function (P=0.03) than controls. 
Also, higher levels of anxiety and depressive symptoms, somatic and cognitive 
complaints, sleep problems and health distress were found, as well as lower levels of 
general health perceptions, social functioning and energy (P <0.05). No differences 
in wellbeing reports were found between patients on regimens containing either 
efavirenz or nevirapine and patients on cART without  these drugs (P >0.05).Patients 
had a smaller BPF(P=0.04) and thalamus (P=0.05) than controls. A lower BPF was 
related to worse motor function and information processing speed in the patients. 
A smaller thalamus volume was related to lower motor function in the patient group 
and lower speed of information processing in the controls. 
 No profound deficits were found in the current study. The present results demonstrate 
that HIV has a minor impact on brain, cognition, and wellbeing among HIV-infected 
patients who are otherwise healthy and maintained on a good control of cART. 
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Introduction
Over the past decades a substantial amount of research has been done on cognitive 
functioning and brain abnormalities in HIV-infected patients. The introduction of 
combination antiretroviral therapy (cART) has led to a marked improvement in survival, 
as well as a considerable decrease in the incidence of HIV-associated Dementia (HAD). 
Impairments in cognitive functioning are still being reported, but may be more subtle 
in nature [1-4]. Despite these great improvements, the possibility of brain dysfunctions 
and problems in memory functioning and concentration remain major concerns for 
HIV-infected people, despite long term successful treatment with cART. Recent 
estimates of the prevalence of cognitive impairment in the cART era vary greatly, and 
range from 18 to 69 percent of the HIV-infected patients from different parts of the 
world [1,4, 5-7]. The actual prevalence of cognitive impairment is under debate, which 
might be overestimated when the updated criteria for HIV-associated neurocognitive 
disorders (HANDs) are applied [8]. The criteria for asymptomatic neurocognitive 
impairment (ANI) may be too lenient, leading to a high false positive rate in classifying 
patients with cognitive impairment [9,10]. Deficits in many different cognitive domains 
have been demonstrated over the years, with speed of information processing, 
attention/working memory, learning and executive functioning being the domains 
most sensitive to HIV-related cognitive changes [10-12].
 Furthermore, brain MRI studies have demonstrated volumetric changes in both 
grey and white matter in HIV-infected patients [13-16]. Specifically, volume reductions 
of the amygdala, caudate nucleus, thalamus and hippocampus, as well as neocortical 
regions such as the cingulate cortex have been described [17,18]. The degree of 
atrophy due to HIV infection has been shown to correlate with lower cognitive 
performance in some [13,19,20], but not in other studies [17]. Moreover, cognitive 
complaints and impairments may affect patients’ wellbeing and may interfere with 
work, social interactions and daily functioning [21-23]. Also, medication characteristics 
may have effects on wellbeing. For instance, efavirenz is well-known for its association 
with neuropsychiatric symptoms and there are indications that nevirapine is related to 
sleep disturbances and neuropsychiatric complications in some patients [24-27]. So 
far, most studies on the relation between cognitive function and neuroimaging data 
of HIV infected patients in the post-cART era have focused on specific findings in 
isolation. Often, measures of subjective wellbeing [14,15,17] or a well-matched control 
group are lacking [19,20]. The present study therefore integrates results from 
extensive neuropsychological assessment on multiple domains, subjective wellbeing 
reports and MRI volumetric measures in succesfully treated HIV-infected patients on 
long term cART, in comparison with a matched, HIV-negative, control group. 
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Methods
Participants
This study is part of the Art-NeCo study, a prospective Dutch cohort study on neuro- 
cognition in HIV-infected patients on long term effective combination antiretroviral 
therapy (cART) and comprises 102 HIV-infected patients and 56 matched controls 
included between January 2012 and January 2014. Consecutive patients on cART for 
at least one year with HIVRNA in plasma <20 copies/ml for at least one year and 
without active opportunistic infections, malignancy and neurosyphilis were recruited 
through their treating physicians at the two participating centers, that is, Radboud 
University Medical Center in Nijmegen and the Rijnstate Hospital Arnhem. Patients 
were selected regardless of the presence of signs or symptoms of suspected 
cognitive impairment or subjective cognitive complaints. Control participants were 
recruited among spouses and acquaintances of the HIV-infected patients, via the 
network of the researchers and through advertisements in local newspapers and 
websites in order to group-match on age, sex and educational level. Both patients 
and controls had to be between 18 and 70 years of age and fluent in Dutch language. 
Exclusion criteria were current recreational drug or alcohol abuse, and a history of 
psychiatric or neurological disorder (unrelated to HIV infection in the patient group). 
Exclusion criteria specifically for HIV-infected patients were active opportunistic 
infections, pregnancy, malignancy or neurosyphilis. Contra-indications for the structural 
MR examination were claustrophobia and metal implants. Medical ethical approval 
for this study was obtained from the Medical Review Ethics Committee region 
Arnhem- Nijmegen (CMO# 2011/267) and written informed consent was obtained 
from all participants. HIV-1 status of patients was determined by enzyme-linked 
immunosorbent assays (ELISA) and a Western Blot confirmatory test, and with a 
rapid HIV test in healthy controls. 
Neuropsychological assessment
All participants completed an extensive neuropsychological assessment, covering 
eight cognitive domains: language (Letter fluency task), speed of information 
processing (WAIS-III Digit Symbol, Trail Making Test Part A, Stroop Color Word Test 
parts I and II), learning (Rey Auditory Verbal Learning Test, Location Learning Test – 
Revised), memory (Rey Auditory Verbal Learning Test, Location Learning Test – 
Revised), executive functioning (Brixton Spatial Anticipation Test, Trail Making Test 
Part B, Zoo Map Test, Stroop Color Word Test interference score), attention/working 
memory (PASAT, WAIS-III Letter-Number Sequencing, Corsi Block Tapping Task), 
motor function (Grooved Pegboard), visuoconstruction (Rey-Osterrieth Complex 
Figure Test, copy trial). Furthermore, symptom validity was assessed with the 15-item 
version of the Amsterdam Short Term Memory Test (ASTM) (cut-off score < 84) to 
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detect possible underperformance unrelated to HIV-associated cognitive impairment 
[28]. Participants performing below the cut-off were removed from the statistical 
analyses. Education level was determined using seven categories in agreement with 
the Dutch educational system (1=less than primary school; 7=academic degree) 
[29]. The Dutch version of the National Adult Reading Test was assessed in order to 
estimate the premorbid intellectual level. Tests were selected to be sensitive to small 
differences in ability. The assessment took approximately 120 minutes to complete 
and was administered by trained neuropsychologists. A detailed description of the 
assessment can be found in Janssen et al. [30] and elaborate test descriptions in 
Bouma et al. [31] and Lezak et al. [32].
Questionnaires
Four questionnaires were administered to measure the self-report levels of psychological 
distress, anxiety and depressive states, subjective cognitive complaints, and quality 
of life.
 First, the Dutch version of the Symptom Checklist 90-Revised (SCL-90-R) was 
administered to measure psychological distress on eight subscales (Agoraphobia, 
Anxiety, Depression, Somatic complaints, Cognitive performance difficulty, Interpersonal 
sensitivity, Anger-hostility, Sleep disturbances) and a total score [33]. Higher scores 
indicate higher levels of psychological distress.
 The Dutch version of the Hospital Anxiety and Depression Scale (HADS) was 
administered to assess the experience of anxiety and depressive complaints, with 
higher scores indicating higher levels of experienced anxiety and depressive states 
[34,35].  
 Reports of subjective complaints were assessed using the Dutch version of 
the Cognitive Failures Questionnaire (CFQ) consisting of  four subscales (Absent-
mindedness, Absentmindedness in Social Situations, Names and Words, Orientation) 
and a total score, with higher scores indicating more cognitive problems [36,37].
 The Medical Outcome Study-HIV Health Survey (MOS-HIV) is a HIV specific 
questionnaire to measure general health perceptions and quality of life on ten 
dimensions: General Health perceptions, Pain, Physical functioning, Role functioning, 
Social functioning, Energy/Fatigue, Mental health, Health distress, Cognitive functioning, 
Quality of life and Health transition. Higher scores indicate higher quality of life [38].
MRI data acquisition and analyses
Participants without contraindications underwent an MR examination. All MR 
examinations were performed on the same scanner, a 3T Magnetom Trio (Siemens, 
Erlangen, Germany). Whole-head structural MR images were acquired with a 3D 
T1-weighted MP-RAGE sequence (inversion time (TI)= 1000ms, repetition time (TR) 
= 2300ms, echo time (TE) = 4.71ms, 12° flip-angle, field of view (FOV) =256mm, 192 
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sagittal slices, slice thickness=1mm, voxel-size=1x1x1mm3). All scans were visually 
screened by two radiologists for relevant clinical abnormalities.
 To determine gray matter, white matter and cerebrospinal fluid (CSF) volumes, 
the structural images were segmented into gray matter, white matter, and CSF with 
the VBM8 toolbox (http://dbm.neuro.uni-jena.de/vbm.html) in SPM8 (Wellcome Trust 
Centre for Neuroimaging, University College London, London, UK;://www.fil.ion.ucl.
ac.uk/spm) using priors (thorough clean up, for the rest default setting).
 Variability in head size between participants was controlled for in statistical 
analyses by using relative grey and white matter volumes using the formulae: grey 
matter: (grey matter volume (GM) / total intracranial volume (TIV)) × all patient TIV 
mean; white matter: (white matter volume (WM) / total intracranial volume (TIV)) × all 
patient TIV mean, (TIV = gray matter volume + white matter volume + cerebrospinal 
fluid volume (CSF)) [39]. Furthermore, Brain Parenchymal Fraction (BPF) was 
calculated as an estimated measure of global brain atrophy (BPF = (GM+WM) / 
(GM+WM+CSF) [40]. 
 To determine total volumes (in mm3) of the amygdala, caudate nucleus, hippo- 
campus, and thalamus per participant, automatic segmentation of these structures 
was performed with FSL5.0.8 FIRST (Analysis Group, FMRIB, Oxford, UK) [41,42]. 
This method is based on Bayesian statistical models of shape and appearance for 
subcortical structures from 317 manually labeled T1-weighted MR images. To fit the 
models, the probability of the shape given the observed intensities is used [43]. After 
segmentation, volumes were calculated using MatlabR2014B (MathWorks; Natick, 
MA, USA). Only boundary-corrected data were used. Visual inspection of the 
segmented structures projected onto the T1-weighted MRI scans was done using 
MRIcroN 2014 (www.mricro.com/mricron) to check if the segmented structures align 
with the same structures on the T1. The MRI dataset of one control participant was 
removed due to failed segmentation.
 Absolute total volumes were transferred to SPSS 20.0 for Windows (Lead 
Technologies Inc. SPSS Inc., Chicago, IL, USA), and were subsequently adjusted for 
Brain Parenchymal Fraction (BPF). 
Statistical Analyses
Raw test scores of the neuropsychological assessment were transformed into 
standardized z-scores based on the distribution of the control group and patient 
group together; higher scores indicate a better performance for all the tests. Next, 
domain scores were calculated by averaging the z-scores of the tests that contributed 
to each of the cognitive domains [44]. 
 Also, the Frascati criteria were applied to classify HAND. According to these 
criteria, participants are classified as having asymptomatic neurocognitive impairment 
(ANI) if test scores are at least 1 standard deviation (SD) below the normative mean 
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in two cognitive domains in the absence of interference with everyday functioning. 
Mild neurocognitive impairment (MND) is classified if a participant satisfies the same 
criteria, and if they present with mild everyday functional impairment. HIV-associated 
dementia (HAD) is classified when test scores are at least 2 SDs below the normative 
mean in at least two cognitive domains and when marked interference in everyday 
functioning is present.
 Between-group differences in cognitive functioning and grey matter, white 
matter, amygdala, caudate nucleus, hippocampus, and thalamus volumes and BPF 
were examined for each cognitive domain and for each volume with general linear 
model univariate analysis of variance (ANOVA). Age, sex and estimated IQ were 
entered as covariates. 
 Multiple hierarchical regression analyses were performed to examine the contribution 
of Brain Parenchymal fraction and the volumes segmented with FSL FIRST on 
cognitive functioning for patients and controls separately. 
 Multivariate general linear model (GLM) analyses of variance were performed for 
between-group differences in the subscales of the questionnaires. Multivariate GLM 
analyses were also performed to analyze differences in the subscales of the 
questionnaires between patients on cART containing either efavirenz or neviparine 
and patients on a regimen without efavirenz or neviparine. Age, sex and estimated IQ 
were entered as covariates for all analyses. 
 A multiple hierarchical regression analysis was performed to investigate the 
influence of HIV infection on overall cognition (mean of the standardized cognitive 
domain scores). Demographic variables were entered at the first stage of the model, 
wellbeing factors at the second level, brain correlates at the third and HIV status at the 
last level of the model. Effect sizes (partial eta-squared) were computed for all 
analyses and alpha was set at 0.05.
Results
Three patients and one control participant performed below the cut-off of the symptom 
validity test and were therefore removed from all analyses. Furthermore, two patients 
dropped out due to medical reasons unrelated to HIV status (stroke, epilepsy) and 
two due to missing data (not all tests could be completed due to an eye condition or 
to logistical reasons). The total sample therefore consisted of 95 HIV-1 infected 
patients and 55 control participants. Table 1 shows the demographic characteristics 
and the frequency of cognitive impairment classified with the Frascati criteria. 
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Neuropsychological Assessment
After adjusting for age, sex and estimated IQ, a significantly lower performance in 
cognitive functioning was found in patients compared to controls on the cognitive 
domains speed of information processing: F(1, 144)=6.9, P=0.01, ηp
2=0.05 and 
motor function (F(1,145)=4.3, P=0.04, ηp
2=0.03). No significant differences were 
found on the other cognitive domains (F-values ≤3.4 and ηp
2 ≤0.02) (Fig. 1). 
Table 1   Demographic variables.
Characteristic Patients (N=95 ) Controls (N=55)
Age (years) [mean (SD)] 48.2 (10.1) 50.7 (11)
Sex 83 (87.4%) men 
MSM: 74(89.2%)
12 (12.6%) women
44 (80%) men
 MSM: 13(29.5%)
11 (20%) women
Marital status
Married/partner 64 (67.4%) 49 (89.1%)
Single 31 (32.6%) 6 (10.9%)
Nadir CD4 cell count (cells/µL) [mean (IQR)] 214 (100-305) n.a.
Duration HIV-infection (years) [mean (SD)] 9.34 (6.3) n.a.
Duration cART treatment (years) [mean (SD)] 7.9 (5.7) n.a.
Regular alcohol use1 30 (31.9%) 24 (43.6%)
Regular drug use2 10 (10.5%) 3 (5.5%)
Education level [median (range)]3 6 (2-7) 6 (3-7)
Estimated IQ [mean (SD)] 98.3*(13.9) 103.4 (14.1)
Cognitive impairment cf. Frascati 39 (41.1%) 17 (30.9%)
Asymptomatic Neurocognitive Impairment (ANI) 34 (35.8 %) 17 (30.9%)
Mild Neurocognitive Disorder (MND) 5 (5.3 %) n.a.
HIV Associated Dementia (HAD) 0 (0 %) n.a.
HADS > cut-off (total score >12) 23 (24.3%) 12 (21.8%)
1Regular alcohol use is use of alcohol for three or more times a week or binge drinking on two subsequent 
days. 2Regular drug use is use of a drug for four times or more times a month. 3Education level was 
recorded using seven categories based on the Dutch educational system, which can be related to the 
Anglo-Saxon system using years of education: 1:1-5 years, 2:6 years, 3:7-8 years, 4:7-9 years, 5:7-10 
years, 6:7-17 years and 7: >18 years. *p<0.05. n.a. = not applicable. MSM = Men who have sex with men
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MRI
MRI scans were made in 85 HIV-infected patients and 40 controls (after excluding 
participants with contra-indications and who performed below the cut-off of the 
symptom validity test).
 Univariate analyses showed a significant difference between patients and controls 
in Brain Parenchymal Fraction (F (1,120)=4.2, P=0.04, ηp
2=0.03). No significant 
differences were found in total grey matter (F(1,120=0.1, P=0.78, ηp
2=0) and total 
white matter volume (F(1,120)=1.2, P=0.28, ηp
2=0.01.) (see Fig. 2). Also, patients had 
a significantly smaller thalamus fraction than controls after controlling for age, sex 
and estimated IQ: F(1,120)=3.8, P=0.05, ηp
2=0.03. No significant differences were 
found for the other three brain structures (F values ≤1.9 and ηp
2≤0.02) (see table 2).
 Multiple hierarchical regression analyses revealed a significant contribution of 
BPF in the variance on the cognitive domains speed of information processing 
(R2 change=0.03, F change (1,80) =4.6, P=0.04, beta=0.21) and motor function 
(R2 change=0.05, F change (1,80)=5.3, P=0.02, beta=0.28) in the patient group but 
3
Figure 1  Cognitive domain scores (mean z-scores+SEM) for patients and controls. 
*p<0.05; **p<0.01.
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not in the control group (speed of information processing: R2 change=0, F change 
(1,34)=0.4, P=0.56, beta=0.16; motor function: R2 change=0, F change (1,35)=0.4, 
P=0.53, beta=0.15) after adjusting for age, sex and estimated IQ. These results show 
that a lower BPF is related to a worse information processing speed and motor 
function in the patient group.
 Also, thalamic volume was related to the domain motor function in the patient 
group (R2 change=0.06, F change (1,80)=6.9, P=0.01, beta=0.26) but not in the 
controls (R2 change=0.04, F change (1,35)=2, P=0.17, beta=0.21). Furthermore, a 
significant contribution of thalamic volume in the variance of the domain speed of 
information processing was found in the controls (R2 change=0.10, F change 
(1,34)=4.9, P=0.03, beta=0.38), but not in the patients (R2 change=0.02, F change 
(1,80)=2.8, P=0.10, beta=0.14). Thus, a lower thalamic volume is related to a lower 
motor function performance in the patient group and lower speed of information 
processing in the controls. 
Self-report measures
One patient did not complete the self-report measures, and was therefore not 
included in the following analyses. The multivariate general linear model (GLM) 
analysis for the SCL-90-R showed a significant difference between the scores of the 
patients and controls (F(9,136)=1.9, P=0.05). Subsequent univariate analyses 
showed significant group differences on the subscales Anxiety (F(1,144 =5.1, P=0.03, 
ηp
2=0.03), Depression (F(1,144)=4.6, P=0.03, ηp
2=0.03), Somatic complaints 
(F(1,144)=6.6, P=0.01, ηp
2=0.04), Sleep Problems (F(1, 144)=8.6, P=0.004, 
ηp
2=0.057) and on the total Score (F(1,144)=4.2, P= 0.04, ηp
2=0.03, with patients 
Table 2   Mean MRI Fractions in arbitrary units (+SD) per volume.
MRI values Patients (N=85) Controls (N=40)
Brain parenchymal fraction 0.825 (0.021)* 0.827 (0.022)
Grey mattera 621.2 (45.0) 615.8 (40.5)
White mattera 602.0 (38.8) 610.8 (28.9)
Amygdalab 3.48 (0.56) 3.64 (0.48)
Caudate nucleusb 8.40 (1.07) 8.52 (0.85)
Hippocampusb 9.09 (1.20) 9.46 (1.01)
Thalamusb 19.50 (2.27)* 20.17 (1.73)
*p<0.05; arelative Grey- and White matter: grey matter volume / total intracranial volume (TIV) × all 
patient TIV mean, white matter volume / total intracranial volume (TIV) × all patient TIV mean; b volumes 
are corrected for BPF: total volume / BPF
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reporting higher levels of psychological distress than controls. An overall group 
difference was found on the MOS-HIV (F(11,134)=1.9, P=0.02). Univariate analyses 
showed significant group differences on the subscales General Health Perceptions 
(F(1, 144)=14.6, P=0.001, ηp
2=0.09), Social Functioning (F(1,144)=6.2, P=0.01, 
ηp
2=0.04), Energy/Fatigue (F(1,144)=4.2, P=0.04, ηp
2=0.03), Health distress 
(F(1,144)=7.4, P=0.01, ηp
2=0.05) and Cognitive functioning (F(1,144)=4.3, P=0.04, 
ηp
2=0.03), with patients reporting lower levels of quality of life than the control group. 
No significant group differences were found on the HADS and CFQ (F-values ≤1.9, 
ηp
2≤0.01) (see table 3). Self-reported measures of anxiety and depressive symptoms, 
somatic complaints, sleep problems, health distress, general health perceptions, 
social functioning, energy and subjective cognitive complaints correlated with the 
cognitive domains speed of information processing and motor function (Pearson’s r’s 
ranging from 0.16 to 0.25 and r2 ranging from 0.026 to 0.063). Comparing the 
outcomes on the questionnaires of patients on regimens containing either efavirenz 
or nevirapine and patients without  these drugs in their treatment did not show 
significant differences (F-values ≤1.8, ηp
2≤0.2).
3
Figure 2   Distribution of Grey matter and White matter volumes for patients  
and controls. 
48
Table 3   Mean scores  (±SD) for the self-report measures on psychological 
distress (SCL-90-R), mood (HADS), subjective cognitive complaints 
(CFQ) and quality of life (MOS-HIV).
Patients (n=94) Controls (n=55)
SCL-90-R
Total Score 130.1 (37.4) 115.7 (27.0)*
Agoraphobia 8.0 (2.4) 7.6 (1.4)
Anxiety 13.6 (4.2) 12.0 (3.2)*
Depression 25.0 (8.7) 21.5 (7.6)*
Somatization 18.0 (5.4) 15.6 (4.3)*
Cognitive performance difficulty 14.2 (5.0) 12.5 (3.2)
Interpersonal sensitivity 25.4 (8.8) 24.1 (6.5)
Anger-Hostility 7.6 (2.2) 7.0 (1.6)
Sleep Problems 5.9 (2.6) 4.5 (1.8)*
HADS
Total Score 9.1 (5.8) 9.5 (6.4)
Depression 4.0 (3.1) 4.1 (3.2)
Anxiety 5.1 (3.5) 5.3 (3.8)
CFQ
Total Score 31.2 (13.2) 29.1 (9.5)
Absentmindedness 7.5 (4.5) 6.7 (3.5)
Absentmindedness in social situations 5.5 (2.6) 5.2 (2.2)
Names and Words 5.8 (2.2) 5.3 (1.9)
Orientation 2.9 (2.0) 2.5 (1.5)
MOS-HIV
General Health perceptions 63.2 (22.5) 77.4 (18.7)*
Pain 81.4 (17.5) 80 (20.4)
Physical functioning 85.6 (18.2) 86.4 (15.7)
Role Functioning 83.0 (31.6) 86.4 (29.6)
Social Functioning 84.9 (19.2) 93.5 (13.4)*
Energy/Fatigue 66.9 (18.2) 74.0 (14.0)*
Mental health 74.9 (17.3) 80.5 (14.2)
Health Distress 84.1 (16.3) 91.5 (11.4)*
Cognitive functioning 76.5 (17.8) 82.9 (11.0)*
Quality of life 72.6 (19.1) 79.1 (18.5)
Health transition 56.1 (17.1) 53.2 (18.0)
*p<0.05.
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Multilevel analysis
De demographic variables age, sex and estimated IQ were entered at the first level of 
the multiple hierarchical regression analyses. The subscales depression (SCL-90), 
sleep problems (SCL-90) and general health perceptions (MOS-HIV) were entered at 
the second level, BPF and thalamus were entered at the third level, and HIV status 
was entered at the last level of the model. The dependent variable was overall 
cognition. This final model was statistically significant (F (9, 112)=21.8, P>.0005). 
However, only the predictors age and estimated IQ contributed significantly to the 
model (age: beta=-0.5, t=-6.7, P<.0005; estimated IQ: beta=0.5, t=8.7, P<.0005).
Discussion
In the current study, we combined the results of extensive neuropsychological 
assessment, subjective wellbeing reports and MRI volumetric measures from patients 
on cART with virologically supressed HIV-infection and compared these with a 
matched HIV-negative control group. Overall, we only found small differences between 
HIV-infected patients and healthy controls, with no severe cognitive impairments in 
the patient group. The multilevel analyses did not show an additional effect of HIV 
infection on overall cognition. Patients showed a significantly lower performance on 
measures of speed of information processing and motor function compared with the 
controls, which is in line with other recent studies [10,12]. The cognitive decrements 
found in this study can be characterized as mild abnormalities in mental and motor 
speed. We did not find any abnormalities in cognitive domains such as executive 
functioning and memory, which are frequently reported in other studies [2,45,46]. In 
contrast to the previous studies, our sample consisted of patients on cART with 
suppressed HIV viremia and without severe comorbidities. This is highly representative 
for the HIV patient population in the Netherlands, in which 91% is treated with cART 
and 82% achieve viral suppression on combination therapy [47]. 
 Furthermore, according to the Frascati classification, 41.1% of the patients fulfil 
the criteria for HAND. This proportion is in line with studies using similar inclusion 
criteria [1,48]. However, as noted in the introduction, the Frascati criteria might lack 
specificity, resulting in possible overestimation of the real prevalence of cognitive 
impairment [9]. Indeed, application of these Frascati criteria on our healthy controls 
results in 30.9% fulfilling the criteria for ANI (MND and HAD were not present in the 
control group). A recent study by Su et al. [48] also found similar percentages of 
HAND using the Frascati criteria in the patient group (48%) and in the healthy control 
group (36%). The researchers recommend multivariate normative comparison (MNC) 
for the classification of impaired patients, a statistical method reducing the false 
positive rate while retaining sensitivity in comparison to the Frascati criteria. After 
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application of MNC, they indeed found better specificity, with 17% of the patient 
group showing cognitive impairment and 5% of the healthy control group. MNC in our 
patient sample also reduces the percentage of cognitive impairment to 11%.
 With respect to the structural volumetric MRI, small yet significant volume 
differences in the thalamus and total brain volume were found between the patients 
and controls, with the patient group showing smaller volumes. Also, a higher total brain 
volume was related to a higher performance in motor function and speed of information 
processing in the patient group, but not in the controls. However, the results for the 
thalamus were less consistent. That is, a better performance on motor function was 
related to a larger thalamus in the patients, but a better speed of information processing 
was related to a larger thalamus only in the controls. There is abundant evidence that 
the thalamus actively regulates information transmission to the cortex and between 
cortical areas and contributes to learning, memory processes, set-shifting, language 
and movement monitoring and control [49,50]. Interestingly, Chiang et al.[18] reported 
bilateral thalamic atrophy in HIV-infected patients, which was also found to be related 
to cognitive impairment. However, their sample consisted of CDC stage C AIDS 
patients. Ances et al. [17] did not found volume reductions in the thalamus in HIV-infected 
patients, regardless of cART treatment. Also, others consistently report atrophy of the 
caudate nucleus in HIV patients [51]. However abnormalities in this region were not 
present in the current study. CNS pathology was highly prevalent in the pre-cART era. 
However, as Gelman points out, specific neuropathological changes are no longer 
found in virologically suppressed HIV-infected patients. He argues that the relation with 
HAND is therefore driven by subtler and potentially reversible neurometabolic changes, 
such as those associated with synaptic transmission and neural plasticity [52]. 
 In addition, we found that HIV-infected patients perceived their wellbeing and 
quality of life as worse than controls. Lower psychological wellbeing and quality of life 
are frequently reported in HIV-infected patients, and in other chronic illnesses like 
diabetes, multiple sclerosis and heart disease [23,53,54]. However, it should be stressed 
that the extent of these complaints were mild (scores were often below clinical cut-off 
points) and no group differences were found on severe anxiety and depressive complaints 
(HADS). Significant correlations were found between self-reported measures of Anxiety 
and Depressive symptoms, Somatic complaints, Sleep problems, Health distress, 
General health perceptions, Social functioning, Energy and subjective Cognitive 
complaints and motor function and speed of information processing, but the strength 
of these relations was very weak. Interestingly, no significant correlation was found 
between the subscale cognitive functioning of the MOS-HIV and the performance on 
the cognitive domains information processing speed and motor function. Patients on 
a cART regimen containing either efavirenz or nevirapine did not show lower levels of 
psychological wellbeing in comparison to patients on a cART regimen without these 
drugs.
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 The integrative design of the current study provides a comprehensive overview 
on the health status of a representative Dutch HIV-infected population. Another 
strength of this study is the application of a symptom validity test.  While it is important 
to include a symptom validity test when interpreting cognitive test results in patients 
with chronic disease, our findings showed that only a small number of patients shows 
evidence for underperformance (3 patients and 1 control scored below the cut-off of 
the symptom validity test), especially compared to large percentages often reported 
in other patient groups [28,55]. 
 There are a few limitations of the current study. First, with our cross-sectional 
design we found small decrements in information processing speed and motor 
function in HIV-infected patients. However, to investigate cognitive decline over time, 
longitudinal studies are needed. Second, we only included successfully treated 
HIV-infected patients on cART. Therefore, the results cannot be generalized to 
patients who do not receive cART or who have a detectable  viral load for other 
reasons (e.g non adherence).
 To summarize, our results showed a lowered performance on the cognitive 
domains information processing speed and motor function in combination with a 
slightly smaller thalamus and total brain volume in the patient group compared to a 
matched HIV-negative control group.  Also, patients reported more complaints on 
several wellbeing dimensions, but these were often below clinical cut-off points and 
could not explain the differences found in cognitive performance.
 In conclusion, no profound deficits were found in our study with a successfully 
treated HIV-infected patient group on long-term cART. The present results clearly 
demonstrate that HIV infection has a relatively minor impact on brain, cognition, and 
psychological functioning among patients who are otherwise healthy and maintained 
on a good control of their antiretroviral medications. As HIV infection is now a chronic 
illness and life expectancy increased over the years, future research should focus on 
longitudinal follow-up assessments in cognitive functioning and brain abnormalities. 
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Abstract
The objectives of the current study were to examine cognitive decline in relation to 
psychological wellbeing, HIV disease and treatment characteristics and baseline 
variables over a one-year period of time in a group of HIV-infected patients on long 
term cART with undetectable viral load in comparison to a HIV-negative control 
group. Eighty-two of 95 patients and 43 of 55 controls who completed a baseline 
assessment for the Art-NeCo study underwent a follow-up neuropsychological 
assessment. A repeated-measure General Linear Model (GLM) analysis was 
performed to compare the performance at follow-up in comparison to baseline 
between the patients and controls. Reliable change indices (RCIs) were computed as 
a measure of significant change in cognitive function. Compared to controls, patients 
overall performed worse on the domain speed of information processing. In the 
patient group a worse performance at follow-up was present for the verbal fluency 
domain compared to the controls, in the absence of a baseline group difference. 
For the executive function domain, no group differences were found at follow-up, but 
the patients performed worse than the controls at baseline. We found that cognitive 
decline was related to more frequent use of recreational drugs and a somewhat 
heightened level of irritability and more somatic complaints at baseline. However, the 
decliners did not differ from the non-decliners on any of the HIV-related variables. 
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Introduction
HIV-associated neurocognitive disorders (HAND) are still frequently found in the 
cART era [1,2]. Whereas the prevalence of most severe forms of HAND have vastly 
declined, milder forms are still being reported. Over the years, deficits in various 
cognitive domains have been demonstrated, with speed of information processing, 
attention, memory and executive function showing the strongest impairments [2,3-5].
Several longitudinal studies on neurocognitive decline and potential predicting 
factors have been performed [4,6,7]. In their review Cysique et al. found that cART is 
associated with stable neuropsychological functioning over time, especially in 
clinically stable patients with undetectable plasma viral loads over a long period of 
time [8]. Nevertheless, a longitudinal study with a large study sample showed 
cognitive decline at follow-up assessments in 21% of patients who were cognitively 
unimpaired at baseline [7]. A study in HIV-infected patients with HIV-related cognitive 
impairment showed persistent impairment in 62.8% of the patients at follow-up (6-124 
months) despite treatment with cART [4]. 
 Some studies used available normative data to determine significant and clinically 
relevant cognitive change in individual patients. In one study, 192 patients with HIV 
and 101 HIV negative controls from China were followed for 1 year and the results on 
cognitive assessment of the controls were used to derive regression-based norms for 
change [9]. The scores that were obtained using this approach were adjusted for 
practice effects, regression toward the mean, and other factors that may have an 
effect on normal test-retest variability in neurologically stable people (e.g. test-retest 
interval, demographics, and overall baseline neuropsychological competence). 
Twenty-seven percent of the patient group showed significant cognitive decline over 
a one-year period. This decline was predicted by having AIDS at baseline, lower nadir 
CD4 cell count and failure of viral suppression on cART. Cognitive decline was also 
related to decreased independence in activities of daily living. Another study using a 
subset of patients from the CHARTER cohort also investigated cognitive change 
using a similar approach. Cognitive change of 436 HIV-infected patients who 
underwent 4 to 7 study visits was determined with z-scores based on published 
normative data [10]. Results showed cognitive decline in 22.7% of the patients, 60.8% 
remained stable and 16.5% improved. Predictors for cognitive change were 
time-dependent treatment status (ART status, immunosuppression, and plasma and 
CSF HIV RNA load), indicators of disease severity (current hematocrit, albumin, total 
protein and aspartate aminotransferase), premorbid IQ, depressive symptoms, and 
lifetime psychiatric diagnoses.
 So far, previous studies that used a statistical approach to determine cognitive 
change over time included mixed cohorts consisting of both patients on cART and 
cART naïve patients. In the current study cognitive change was investigated in a 
4
60
group of HIV-infected patients on long term cART treatment with undetectable viral 
load in comparison to a matched HIV-negative control group. The aim of this study is 
twofold. First, we examined cognitive decline over a one-year period by calculating 
test-retest scores for a comprehensive neuropsychological assessment. Second, 
we identified which HIV disease and treatment characteristics as well as which 
psychological and baseline variables are associated with this decline. 
Methods 
Participants
All participants were recruited as part of the Art-NeCo study (a prospective Dutch 
cohort study on NeuroCognition in HIV-infected patients on long term effective 
combination antiretroviral therapy; cART) [5]. Baseline assessment was performed in 
95 HIV-infected patients and 55 HIV-negative controls. An extensive description of all 
inclusion and exclusion criteria have been published previously [5]. Of these 
participants, 82 patients and 43 controls underwent a follow-up neuropsychological 
assessment yielding a 16,7% (25/150) attrition rate. Reasons for dropping out were 
lack of time, lack of interest to participate again and personal reasons like problems 
at work or at home, unrelated to HIV status or symptom validity testing. No significant 
differences were found between completers and non-completers on the baseline 
variables age, education level, sex distribution, sexual orientation, performance on 
cognitive domains at baseline, nadir CD4, time on cART or duration of HIV infection 
(p > .05). At baseline, 34 patients fulfilled the criteria for asymptomatic neurocognitive 
impairment and 5 for mild neurocognitive disorder. None of the patients fulfilled the 
criteria for HIV-associated dementia. The cognitive decrements were mild in nature 
and cognitive domains that are typically affected by HIV infection like executive 
functioning and memory were unimpaired in our patient sample (see Janssen et al. 
2015).
Procedures
At both study visits participants completed a comprehensive neuropsychological 
assessment measuring eight cognitive domains (speed of information processing, 
learning, memory, executive function, attention/working memory, motor function, 
 visuoconstruction and verbal fluency). Also, a self-report questionnaire was completed, 
the Symptom Checklist – Revised (SCL-90-R), to measure psychological distress and 
somatic complaints. At baseline, a questionnaire on alcohol and other recreational 
drug use was completed by all participants and a rapid HIV test was performed in all 
controls. Also, participants without contraindications underwent an MR examination 
at baseline and symptom validity testing was performed. Baseline details of the 
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Art-NeCo in- and exclusion criteria, the neuropsychological test battery and the MRI 
analyses have been reported in a previous publication [5]. Medical ethical approval 
for this study and written informed consent from all study participants were obtained 
(CMO Region Arnhem-Nijmegen #2011/267).
Statistical Analyses
Raw test scores of the individual tests of the baseline and follow-up neuropsycholog-
ical test battery were transformed into standardized z-scores. Test scores were 
transformed on the basis of the baseline test score distribution of the patient- and 
control group taken together, with higher scores indicating a better performance for 
all tests. Cognitive domain scores were computed by averaging the contributing tests 
to each of the cognitive domains [11]. 
 A repeated measures General Linear Model (GLM) was executed to compare the 
performance at follow-up in comparison to baseline between the patients and 
controls. Age, sex and estimated premorbid IQ were entered as covariates. Alpha 
was set at 0.05 for all analyses.
Determination of cognitive decline
Next, analyses were performed to establish which patients deteriorated at follow-up 
compared to baseline, using the change in performance in the controls as benchmark. 
Reliable change indices (RCIs) were computed per patient as a measure of individual 
significant change on the cognitive tests after a one-year retest interval. According to 
the procedure outlined in Chelune et al. [12], difference scores of the individual test 
scores between the first (T1) and second (T2) assessment were calculated for each 
individual patient (ptx) and a mean difference score was calculated for the control 
group as a whole (ct). The difference score for each patient was subtracted by the 
mean difference score of the control group as whole, using the following formula: 
(T2ptx – T1ptx) – (T2ct – T1ct). Next, the standard error of difference (Sdiff) was calculated 
for each of the test scores per patient, following the procedures outlined in Maassen 
[13], using the following formula: 
Finally, the difference score of each patient per test was divided by the standard error 
of difference in order to calculate the RCI index per test per patient. Next, individual 
RCIs per test were averaged into the eight cognitive domains. Patients with a mean 
RCI domain score ≥ -1.645 [12] were considered as ‘cognitive decliners’ on that 
domain. Subsequently, individual patients were classified as either overall cognitive 
decliner, defined as showing a reliable decline on at least one cognitive domain, or non- 
decliner. Subsequently, overall cognitive decliners were compared to non-decliners 
4
62
on the SCL-90-R subscale performance, alcohol and drug use, HIV disease and 
treatment variables, age and MRI measures at baseline. 
Results
Only participants who passed symptom validity testing were included in all analyses 
[5]. Mean follow-up interval was 12.2 months (range 10.1-18.6 months). Table 1 shows 
the baseline demographic characteristics, SCL-90-R scores and MRI measures of 
the patients and controls who participated in the follow-up assessment and the HIV 
disease and treatment characteristics for the patients.
Baseline vs. follow-up cognitive performance
Figure 1 shows the baseline and follow-up cognitive performance for the patients and 
controls for the individual cognitive domains. Repeated-measure GLM analyses 
showed an overall better performance at follow-up than at baseline for both groups 
for the domains speed of information processing, executive function and visuocon-
struction (F-values > 4.6, p < .05). An overall group difference was found on the 
domain speed of information processing (F = 5.1, p = .025, ηp
2 = .041), with the 
patients performing worse than the controls. A significant Group × Time interaction 
was found for the domains executive function (F = 10.1, p = .002, ηp
2 = .077) and 
verbal fluency (F = 4.2, p = .04, ηp
2 = .034). Post-hoc t-tests demonstrated that at 
follow-up, but not at baseline, the performance of the patients on the verbal fluency 
domain was worse than the controls (t(123) = -2.129, p < .05 and t(123) = -0.666, 
n.s., respectively). Between-group differences were found at baseline, but not at 
follow-up, for the domain executive function (t(123) = -2.249, p < .05 and t(123) = 
-0.493, n.s., respectively).
Cognitive decliners vs. non-decliners
Of the total group of 82 patients, 7 patients showed cognitive decline on the domain 
verbal fluency (8.5%), 2 on the domain visuoconstruction (2.4), 1 on the domain 
speed of information processing (1.2%) and 1 on motor function (1.2%). No decliners 
were found in any of the other domains. In total, 11 patients were classified as being 
overall cognitive decliners (13.4%). These cognitive decliners were subsequently 
compared to the non-decliners on SCL-90-R subscale performance, alcohol and 
drug use, HIV disease and treatment variables, age and MRI measures at baseline. 
The cognitive decliners reported more complaints on the subscales somatic 
complaints (F(1,81)=5.4, p<.05) and anger-hostility (F(1,81)=5.9, p<0.02) of the 
SCL-90-R at baseline compared to the non-decliners. With respect to any of the other 
baseline characteristics, the proportion of frequent users of recreational drugs was 
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Table 1   Demographic variables, SCL-90-R, MRI correlates and treatment 
 characteristics at baseline. 
Characteristic Patients (n = 82) Controls (n = 43)
Age (years) [mean (SD)] 48.7 (9.9) 51.4 (11.1)
Sex 72 (87.8%) men
10 (12.2%) women
34 (79.1%) men
9 (20.9%) women
Education level [median ( range)]3 6 (2-7)* 6 (4-7)
Estimated IQ [mean (SD)] 98.7* (14) 106.8 (11.4)
Nadir CD4 cell count (cells/µL) [mean (IQR)] 222 (100-310) -
Duration HIV-infection (years) [mean (SD)] 9.6 (6.4) -
Duration cART treatment (years) [mean (SD)] 8.1 (5.8)  -
Regular alcohol use1 25 (30.5%) 18 (41.9%)
Regular drug use2 7 (8.5%) 3 (7%)
SCL-90-R [mean (SD)]
Total 131 (38.3) 114 (26.2)
Agoraphobia 8 (2.3) 8 (1.2)
Anxiety 14 (4.4) 12 (3.3)
Depression 25 (8.9) 21 (6.6)
Somatic complaints 18 (5.5) 15 (4.3)
Cognitive performance difficulty 14 (5.1) 12 (3.4)
Interpersonal sensitivity 25 (9.1) 23 (6.4)
Anger-hostility 8 (2.3) 7 (1.5)
Sleep disturbances 6 (2.6) 4 (1.6)
MRI volumetry [mean (SD)]
Grey matter volume4 619.3 (46.1) 613.8 (39.6)
White matter volume4 602.8 (39.8) 610.5 (25.7)
1Regular alcohol use is use of alcohol for three or more times a week or binge drinking on two subsequent 
days. 2Regular drug use is use of a drug for four times or more times a month. 3Education level was 
recorded using seven categories based on the Dutch educational system which uses education levels 
instead of years of formal education (approximate Anglo-Saxon equivalent in years of education is 
presented between brackets): Level 1 = less than 6 years of primary education (1-5); Level 2 = 
completed primary education (6), Level 3 = more than six years of primary education, without a 
secondary school diploma (7-8), Level 4 = lower vocational training (7-9); Level 5 =  advanced 
vocational training or lower professional education (7-10);  Level 6 = advanced professional training or 
upper secondary school (7-17); Level 7 = academic degree (>18 years).  4relative Grey- and White 
matter: grey matter volume / total intracranial volume (TIV) × all patient TIV mean, white matter volume / 
total intracranial volume (TIV) × all patient TIV mean; *p<0.05.
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Figure 1   Mean cognitive domain scores for the patients and controls at baseline 
and one-year follow-up. 
* = significant main effect of Group, p <0.05; ×* = significant Group × Time interaction, p<0.05.
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higher in the cognitive decliners than the non-decliner group (χ2(1) = 6.56, p<.01). 
No differences were found between both groups on any of the other baseline or 
HIV-related baseline characteristics. 
Discussion
The present study investigated cognitive change over a one-year period in a 
virologically stable HIV-infected patient group in comparison to a healthy matched 
control group. Also, we examined whether HIV disease and treatment characteristics 
and psychological baseline variables were associated with cognitive decline.
 Compared to the controls, the patients overall performed worse on the domain 
speed of information processing, but no group × time interaction was found for this 
domain. For the domain verbal fluency, a group × time interaction effect was found, 
showing a worse performance at follow-up in the patient group compared to the 
controls, in the absence of a baseline group difference. For the domain executive 
function, no group difference was found at follow-up, but the patients performed 
worse than the controls at baseline. Our findings clearly show that a lower performance 
in speed of information processing, both at baseline and follow-up, is a robust finding, 
in line with previous studies [2,14] that also report impairments in this domain in 
HIV-infected individuals on cART. With respect to the follow-up performance 
difference in the domain verbal fluency for the patients, it is interesting to note that 
while both groups improve on an absolute level, the improvement in the patients was 
smaller than in the controls. Also, it should be noted that this domain only consists of 
one test, which also relies on processing speed. In the present subsample of the 
ART-NeCo sample, a baseline difference between patients and controls was found 
for executive function, a finding that disappeared at follow-up. Interestingly, this 
baseline difference was not found in the total ART-NeCo group [5], indicating that this 
effect may not be very reliable.  
 At an individual level, most cognitive decliners (based on RCI analyses using the 
control group performance as reference) were found in the domain verbal fluency. 
Comparing the patients who reliably declined on at least one of the cognitive domains 
with those who remained cognitively stable, we found that the decliners reported 
more psychological complaints, specifically related to irritability towards others and 
somatic complaints at baseline. However, the decliners did not differ from the 
non-decliners on any of the HIV-related variables, such as nadir CD-4 cell count, 
duration of infection and years of cART use. This suggests that the higher level of 
somatic complaints cannot be explained by illness-related somatic factors. The 
decliners, however, were more often frequent users of recreational drugs than the 
non-decliners, which may potentially underlie the somewhat lower somatic wellbeing 
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in this subsample [15]. However, it should be stressed that the total group of 
recreational drug users and the number of overall cognitive decliners were small, 
therefore this result should be interpreted with caution. No differences between 
decliners and non-decliners were found on depressive symptoms and anxiety, two 
psychological domains that are frequently related to worse cognitive performance 
[16-18]. 
 A limitation of the current study is the relatively short interval of one year between 
the baseline and follow-up assessment. Particularly in a well-treated HIV-infected 
patient sample without co-morbidities, longer follow-up periods of five or even ten 
years may contribute to our knowledge of long-term consequences of HIV infection 
on cognitive functions in patients who are stable on cART. On the other hand, Becker 
et al. [19] demonstrated cognitive decline already after a six-month follow-up 
assessment, a finding that was found to be related to medication adherence. This 
further emphasizes the need and clinical relevance to examine cognitive decline over 
time in HIV-infected patients. 
 In conclusion, the findings of the current study show that cognitive decline at 
group level is small. We only found a decline in speed of information processing after 
one year. At an individual level, cognitive decline was present in only a small number 
of patients and was related to somewhat more psychological distress and more 
frequent use of recreational drugs. No relation between cognitive decline over time 
and HIV disease and treatment characteristics was found. 
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Abstract
The gold standard for evaluating cognitive impairments in HIV-infected patients is to 
administer an extensive neuropsychological assessment. This may, however, be 
time-consuming and hence not always feasible in the clinic. Therefore, several brief 
screening tools have been developed. This study determined the validity of the 
Montreal Cognitive Assessment (MoCA) and the HIV Dementia Scale (HDS) in 
detecting cognitive impairment using both the Frascati and CIND criteria to classify 
cognitive impairment in HIV-1 infected patients.
 The MoCA, HDS and an extensive neuropsychological assessment, covering 
nine cognitive domains, were administered in a group of 95 HIV-infected patients who 
were all on cART and virologically suppressed for at least one year. 
 Results show that the areas under the curve (AUCs) for both the MoCA and the 
HDS were statistically significant, using both the Frascati and the CIND criteria as 
gold standard. However, the AUCs for the MoCA and HDS did not differ significantly, 
regardless of the used classification criteria (Frascati: z=0.37, p=0.35; CIND: 
z=-0.62, p=0.27). Sensitivity of both the MoCA and HDS were low for the 
recommended cut-off scores (Frascati: MoCA (<26)=0.56, HDS (<11)=0.26; CIND: 
MoCA (<26)=0.55, HDS (<11)=0.36).
 Cut-off scores with good sensitivity and adequate specificity could not be 
determined for both screening instruments. Therefore, the HDS and MoCA are not 
recommended as sole instruments to diagnose HIV-associated cognitive impairment. 
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Introduction
The incidence of severe HIV-associated cognitive impairment has significantly 
declined since the introduction of combination antiretroviral therapy (cART), while 
milder forms of cognitive decrements continue to be prevalent and increase with age. 
Recent results from the CHARTER study demonstrated that 44% of HIV-infected 
patients on cART, without marked comorbidities, fulfilled the criteria for milder forms of 
HIV-associated neurocognitive disorder (HAND) [1]. These neurocognitive impairments 
may have a great impact on functioning in vocational settings or on academic 
achievements. Furthermore, cognitively impaired patients are at greater risk of poor 
medication adherence [2].
 The gold standard for adequately evaluating cognitive impairments is to administer 
an extensive neuropsychological assessment, as this method has a high sensitivity 
and specificity. A neuropsychological assessment typically covers a range of cognitive 
domains, such as memory, executive functioning and attention and can be used to 
classify levels of cognitive dysfunction in HIV using the widely used revised HAND 
criteria, referred to as the Frascati criteria [1,3]. Patients are classified as asymptomatic 
or mildly impaired when they show a performance that lies 1 standard deviation (SD) 
below the demographically adjusted normative mean, yet within 2 SD in at least two 
cognitive domains. When a patient obtains a score of at least 2 SDs below the mean 
within at least 2 cognitive domains, he or she is classified as severely impaired. 
Gisslén et al. pointed out however, that a cutoff of -1 SD to classify impairment may 
lead to overestimation of the real prevalence of cognitive impairment [4]. That is, 
given the normal distribution, 15.9% of any population will perform worse than 1 SD 
below the normative mean on a given test. Another way to determine cognitive 
impairment is to use the criteria ‘cognitive impairment, no dementia’ or CIND. Patients 
are classified as having CIND when one or more of the cognitive domains is impaired, 
which may result in less false positives [5]. The CIND criteria define impairment as an 
average performance >1 on the tasks in a cognitive domain (a score of 0 is obtained 
when the performance is in the normal range (-1SD-1SD), a score of 1 when the 
performance is below average (-1SD- -1.65SD) and a score of 2 when the performance 
is impaired (<-1.65SD). The CIND criteria are somewhat more stringent because they 
require at least one of the test scores in a cognitive domain to be lower than -1 SD to be 
classified as impaired.
 The problem with extensive neuropsychological testing however, is that it is often 
time-consuming and requires trained personnel to administer, score and interpret 
[6,7]. To overcome this limitation, several brief screening tools to detect cognitive 
impairment in HIV-infected patients have been developed over the years [8]. 
An example of such a short screening test is the HIV Dementia Scale (HDS) [9]. This 
test consists of items addressing memory, attention, psychomotor functioning and 
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visuoconstruction. The HDS has been shown to be an adequate screening tool in 
HIV-infected patients in detecting severe cognitive impairment, but has been shown 
to be insensitive to milder forms of cognitive deficits [8, 10-12]. 
 Another widely used screening method to detect cognitive impairment is the 
Montreal Cognitive Assessment (MoCA) [13]. This screening test takes approximately 
10-15 minutes to administer and consists of 30 items measuring eight cognitive 
domains. The MoCA is sensitive in differentiating milder forms of cognitive impairments 
and has been validated in patients with Parkinson’s disease, Huntington’s disease, 
substance abuse and Mild Cognitive Impairment (MCI) [14-19]. However, to date few 
studies have investigated the validity of the MoCA in HIV-infected patients [6,7,20,21]. 
Most studies used the Frascati criteria to classify cognitive impairment and none of 
these studies have directly compared the widely known HDS to the MoCA. Ours is 
the first study that investigates the validity of the MoCA and the HDS in HIV-infected 
patients in relation to two sorts of clinical criteria to determine cognitive impairment. 
 The current study focused on a cohort of HIV-infected patients who were all on 
cART and virologically suppressed for at least one year. The primary objective of this 
study was to determine the validity of the MoCA and the HDS in detecting cognitive 
impairment as measured with an extensive neuropsychological test battery, and 
impairment classified with both the Frascati criteria and the CIND criteria. Sensitivity, 
specificity and AUCs of the HDS and the MoCA were assessed. Furthermore, we aimed 
to determine sensitive and specific cut-off scores for both the MoCA and the HDS.
Methods
Participants
A total of 102 HIV-1 infected patients were included between January 16th 2012 and 
January 31th 2014. Consecutive patients were recruited through their treating 
physicians via the outpatient clinic for infectious diseases at the department of 
Internal Medicine in the Radboud University Medical Center in Nijmegen and at the 
same department in the Rijnstate Hospital Arnhem. Patients were eligible if they were 
between 18 and 70 years old, fluent speaker of the Dutch language, had no current 
drug or alcohol addiction, and no history of psychiatric or neurological disorder 
(unrelated to HIV-1 infection in the patients). Inclusion criteria were an HIV-1 infection 
and absence of active opportunistic infections, pregnancy, malignancy, and neuro-
syphilis. HIV status of all patients was determined by enzyme-linked immunosorbent 
assays (ELISA) and a Western Blot confirmatory test. Patients were selected regardless 
of the presence of signs or symptoms of suspected cognitive impairment or subjective 
cognitive complaints. Medical ethical approval was obtained for this study and written 
informed consent was obtained from all participants.
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Neuropsychological Assessment
Participants completed an extensive neuropsychological test battery measuring nine 
major cognitive domains. Tests that are sensitive to measure small or moderate 
differences in ability were chosen and were administered by trained neuropsycholo-
gists. The allocation of tests to the domains was made a priori, according to standard 
neuropsychological practice, psychometric properties of the tests and cognitive 
theory [22]. Also, the domains and tests were based on previous studies that 
examined cognitive impairment in HIV-infected patients [1,23]. 
 Abstract reasoning was assessed by the Raven Advanced Progressive Matrices 
(12-item short form) [24]. Language was assessed with a letter fluency tasks (“K-O-M”; 
1 minute per letter) [25]. The domain Speed of information Processing included the 
Digit symbol Substitution subtest from the WAIS-III, the Trail Making Test part A 
(TMT-A), and the Stroop Color-Word Test (card I and II) [26-29]. Learning was 
assessed both verbally and nonverbally with the Dutch version of the Rey Auditory 
Verbal Learning Test (RAVLT, immediate memory: total score on trials 1-5) and the 
Location Learning Test – Revised (LLT-R, immediate memory: total score on trials 
1-5) respectively [28,30]. The domain Memory was also assessed verbally and 
nonverbally with the same tasks as the domain Learning with the delayed recall trial 
of both tasks. Executive function consisted of three subdomains: Concept shifting, 
Planning and Response inhibition. Shifting was measured with de Brixton Spatial 
Anticipation Test and with the interference score of the Trail Making Test part B 
(TMT-B) [31,27]. Planning was assessed with the Zoo Map test from the Behavioural 
Assessment of the Dysexecutive Syndrome (BADS) [32]. Response inhibition was 
assessed by the Stroop Color-Word Test [29]. Here, the Stroop interference score 
was computed, using the following formula: (time needed for card III-time needed for 
card II)/time needed for card II) [33]. Attention/Working memory was measured with 
the 2.0 and 1.6 Inter stimulus interval (ISI) trials of the Paced Auditory Serial Addition 
Test (PASAT) (60-items per trial), the Letter-Number Sequencing subtest from the 
Wechsler Adult Intelligence Scale, third edition (WAIS-III), and the Corsi Block Tapping 
task [34,26,35]. The domain Motor function was measured with the Grooved Pegboard 
Test (administered for the dominant and non-dominant hand) [36]. Finally, Visuocon-
struction was measured with the copy trial of the Rey-Osterrieth Complex Figure Test 
[37].
 Symptom validity was measured with the short version of the Amsterdam Short 
Term Memory Test (ASTM) (cut-off score <42) [38]. To assess whether patients had 
subjective cognitive complaints, all participants completed the Cognitive Failures 
Questionnaire (CFQ) [39], using a cut-off score of 1.65 SD above the age-adjusted 
normative mean for the CFQ Total Score [40]. Education level was recorded using 
seven categories in agreement with the Dutch educational system (1=less than 
primary school; 7=academic degree). These levels match closely to the following 
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categories in year of education as used in the Anglo-Saxon world [41,42]: Level 1, 
incomplete primary education: 1-5 years; Level 2, primary education: 6 years; Level 
3, incomplete lower secondary education: 7-8 years; Level 4, lower general secondary 
education: 7-9 years; Level 5, vocational education: 7-10 years; Level 6, higher 
general secondary/higher vocational/pre-university education: 7-16 years; Level 7, 
academic degree: 17-20 years. Premorbid intellectual level (estimated IQ) was 
estimated with the Dutch version of the National Adult Reading Test [43].
Montreal Cognitive Assessment
Each participant completed the Dutch version of the Montreal Cognitive Assessment 
(MoCA) [13]. The MoCA consists of 13 tasks measuring the following 8 cognitive 
domains: visuospatial/executive, naming, memory, attention, language, abstraction, 
delayed recall and orientation. The MoCA takes approximately 10-15 minutes to 
complete. A total score was calculated by summing scores of the 13 tasks. The maximum 
score possible is 30 points, with a cut-off score of ≤26 indicative of cognitive 
impairment. One point was added for each participant with 12 or fewer years of formal 
education. 
HIV Dementia Scale 
Each participant also completed the HIV Dementia Scale (HDS) [9]. This test consists 
of 4 items measuring 4 cognitive domains including memory, attention, motor speed 
and visuoconstruction. A total score was calculated by summing scores of the four 
items, with a maximum score of 16. A score of <11 gives an indication of cognitive 
impairment. 
Data analysis
Neuropsychological impairments were classified per task using age- and education- 
adjusted normative data (i.e., using 1 SD and 1.65 SD below the normative mean as 
cut-off scores for mild and severe impairment respectively) [5,22,41]. The performance on 
the neuropsychological assessment as a whole was classified as either ‘impaired’ or 
‘unimpaired’ for each patient using both the Frascati and CIND criteria. In the Frascati 
criteria, impairment of 1 SD below the normative mean must to be present in at least 
two domains for a participant to be classified as ‘cognitively impaired’. Furthermore, 
at least one of the ability deficits has to be outside the motor and sensory perceptual 
domain, in agreement with the updated nosology for HIV-associated neurocognitive 
disorders by Antinori et al. [3]. Performance on the CFQ was used to classify 
cognitively impaired patients in accordance with the Frascati criteria as having 
Asymptomatic Neurocognitive Impairment (ANI; i.e., no subjective complaints, yet 
mild impairments on cognitive testing) or Mild Neurocognitive Disorder (MND; i.e., 
both subjective complaints and mild impairments on cognitive testing). None of 
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the patient fulfilled the criteria for HIV Associated Dementia (HAD; i.e., all patients 
functioned independently at home).
 Using the CIND criteria a patient’s performance was classified as cognitively 
impaired if impairments were present in one or more of the individual cognitive 
domains. Performance on each test was rated as within the normal range (0), below 
average (1) or impaired (2). A score between -1 SD and 1 SD was defined as normal 
performance, a score between -1 SD and -1.65 SD as mildly impaired and a score 
below -1.65 SD was classified as impaired. A cognitive domain was classified as 
impaired when the average rating of tests in that domain was >1 [5]. 
 In agreement with Woods et al., a performance below the cut-off of a symptom 
validity test is likely not the result of actual HIV-associated cognitive impairment and 
must therefore be regarded as an indication of underperformance due to suboptimal 
effort [44]. Participants performing below this cut-off were removed from the statistical 
analyses.
 Data were analyzed by using IBM SPSS version 19.0. Receiver operating 
characteristic (ROC) analyses were performed with the MoCA and the HDS as 
continuous variables and cognitive impairment, classified with both the Frascati and 
the CIND criteria, as state variable. The area under the curve (AUC) was determined 
for each ROC curve, and cut-off scores for both screening tools were determined that 
had good sensitivity accompanied with an acceptable specificity. A cut-off score was 
defined as adequate if a sensitivity of >0.8 was accompanied by an acceptably low 
false positive rate (specificity>0.6) [45].
Results
Three patients performed below the cut-off of the symptom validity test and were 
removed from the analyses. Furthermore, two patients dropped out due to medical 
reasons unrelated to HIV status (recent CVA and severe epilepsy) and two due to 
missing data (in one patient, not all tests could be completed due to an eye condition, 
in another patient the MoCA could not be administered because it was accidentally 
missing in the test battery). The total sample therefore consisted of 95 HIV-1 infected 
patients. Table 1 shows relevant demographic characteristics and the scores on the 
MoCA and HDS. Mean age of the patients was 48.2 years. The mean nadir CD4 cell 
count was 213 cells/mm3 (IQR 100, 305) with all patients virologically suppressed on 
cART (<50 copies/mL). Using the Frascati criteria, 39 of the 95 patients (41%) were 
classified as cognitively impaired. When the CIND criteria were applied, 22 of the 95 
patients (23%) were classified as cognitively impaired. The MoCA identified 33 of the 
95 patients (34.7%) as cognitively impaired, while the HDS identified 12 of 95 (12.6%) 
patients with cognitive impairment, using the clinically established cut-off scores. 
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Table 2 shows neuropsychological performance scores and impairments for the 
cognitive domains and all the tests in the neuropsychological assessment. 
 Figure 1a and 1b show the AUCs of the ROC-analyses for the MoCA and the 
HDS in classifying cognitive impairment as measured with the extensive neuro-
psychological assessment, with impairment classified with both the Frascati and the 
CIND criteria in HIV-1 infected patients. All AUCs were statistically significant (Frascati: 
MoCA AUC=0.70, CI=0.59-0.80, p=0.001; HDS AUC=0.67, CI=0.56-0.79, p=0.005; 
CIND: MoCA AUC=0.66, CI=0.52-0.80, p=0.024; HDS AUC=0.72, CI=0.58-0.86, 
p=0.002). Different cut-off scores with the accompanying sensitivity and specificity 
for cognitive impairment are shown for both screening instruments and the two 
different criteria to classify cognitive impairment in table 3. Cut-off scores with good 
sensitivity (>0.8) and an acceptable specificity (>0.6) could not be determined, 
however. The clinically established cut-off scores resulted in the following sensitivity 
(Se) and specificity (Sp) for the MoCA (<26) and HDS (<11) (Frascati: MoCA Se=0.56, 
Table 1   Demographic variables and performance on the MoCA and HDS.
 
Characteristic HIV-infected patients (N=95)
Age (years) [mean (SD)] 48.2 (10.1)
Sex 83 (87.4%) male
12 (12.6%) female
Nadir CD4 cell count (cells/µL) [mean (IQR)] 213 (100-305)
Duration HIV-infection (years) [mean (SD)] 9.83 (6.3)
Duration cART treatment (years) [mean (SD)] 8.44 (5.7)
Education level (median)1 6
Estimated IQ [mean (SD)] 98.2 (13.9)
Cognitive impairment cf. Frascati 39 (41.1%)
Asymptomatic Neurocognitive Impairment (ANI) 34 (35.8 %)
Mild Neurocognitive Disorder (MND) 5 (5.3 %)
HIV Associated Dementia (HAD) 0 (0 %)
Cognitive impairment cf. CIND 22 (23.2%)
MoCA score [mean (SD)] 26.6 (2.3)
MoCA < cut-off 33 (34.7%)
HDS score [mean (SD)] 13.8 (2.3)
HDS <cut-off 12 (12.6%)
1Education level was recorded using seven categories that can be transferred to years of education: 
1:1-5 years, 2:6 years, 3:7-8 years, 4:7-9 years, 5:7-10 years, 6:7-17 years and 7: >18 years.
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Table 2   Neuropsychological performance and impairments on the cognitive 
domains and on each test per cognitive domain.
Cognitive domains and tests Mean (± SD) N (%) impaired
Abstract reasoning -0.38 (± 1.03) 0 (0%)
Raven Advanced Progressive Matrices 9.09 (± 2.30) 0 (0%)
Language -0.05 (± 1.02) 7 (7.4%)
Letter Fluency Test (“K-O-M”) 40.13 (± 13.20) 7 (7.4%)
Speed of information processing -0.11 (± 0.80) 2 (2.1%)
WAIS-III Digit Symbol substitution 69.32 (± 14.19) 10 (10.5%)
TMT-A 30.54 (± 9.98) 1 (1.1%)
Stroop I&II 51.34 (± 8.46) 1 (1.1%)
Learning -0.04 (± 0.88) 5 (5.3%)
RAVLT (total trials 1-5) 43.22 (± 9.28) 10 (10.5%)
LLT-R (total trials 1-5) 14.97 (± 14.45) 2 (2.1%)
Memory 0.00 (± 0.77) 3 (3.2%)
RAVLT (delayed recall) 8.69 (± 3.02) 9 (9.5%)
LLT-R (delayed recall) 0.64 (± 1.68) 3 (3.2%)
Executive functioning -0.07 (± 0.68) 0 (0%)
Brixton 40.11 (± 5.82) 1 (1.1%
TMT-B 70.28 (± 27.23) 4 (4.2%)
BADS Zoo Map Test 11.38 (± 4.10) 11 (11.6)
Stroop (interference) 0.61 (± 0.33) 5 (5.3%)
Attention/Working memory -0.09 (± 0.71) 3 (3.2%)
PASAT 32.44 (± 9.39) 27 (28.4%)
Corsi Block Tapping task (span forward & 
backward)
6.14 (± 0.69) 0 (0%)
WAIS-III Letter Number Sequencing 11.12 (± 3.20) 3 (3.2%)
Motor -0.09 (± 0.89) 3 (3.2%)
Pegboard ( dominant & non-dominant) 79.26 (± 12.48) 3 (3.2%)
Visuoconstruction -0.10 (± 1.03) 7 (7.4%)
Rey Complex Figure-copy 33.72 (± 3.23) 7 (7.4%)
Domains cores are presented as mean Z scores + SD; individual test scores are presented as mean raw 
scores ± SD. Cognitive domains were classified as impaired when a score of <-1.65 SD was obtained 
in more than half of the tasks in that domain. Test scores were classified as impaired when a score of 
<-1.65 was obtained on the age- and education adjusted score.
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Sp=0.63; HDS Se=0.26, Sp=0.96; CIND: MoCA Se=0.55, Sp=0.58; HDS Se=0.36, 
Sp=0.95). Using a cutoff of 27 for the MoCA slightly increased the sensitivity to 0.74 
when the level of impairment was classified using the Frascati and to 0.64 when the 
CIND criteria were used. Also, the sensitivity of the HDS could be improved to 0.67 
and 0.77 when a cut-off score of 14 was applied, for classification according to the 
Frascati and CIND criteria respectively. The specificity of these cut-off scores 
remained low, however(0.41-0.61). Statistical comparison of the ROC curves for the 
two screening instruments using both the Frascati and the CIND criteria shows that 
the ROC-curves did not differ significantly (Frascati: z=0.025, CI=-0.10-0.15, p=0.69; 
CIND: z=-0.064, CI=-0.22-0.10, p=0.43). 
Figure 1   A ROC-curves for the the  MoCA and HDS using several cut-off points in 
comparison with cognitive impairment classified with the Frascati criteria. 
B ROC-curves for the MoCA and HDS using several cut-off points in 
comparison with cognitive impairment classified with the CIND criteria.
A B
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Table 3   Cut-off points with different degrees of sensitivity and specificity for  
the MoCA and HDS in the identification of cognitive impairment using 
extensive neuropsychological assessment classified with the Frascati  
and CIND criteria. 
Cut-off Sensitivity Specificity
Frascati criteria
MoCA
25.5 0.51 0.77
26.5 0.56 0.63
27.5 0.74 0.50
28.5 0.92 0.36
HDS
11.25 0.26 0.96
13.75 0.49 0.77
14.25 0.67 0.61
14.75 0.69 0.50
15.25 0.80 0.38
CIND criteria
MoCA
25.5 0.55 0.71
26.5 0.55 0.58
27.5 0.64 0.41
28.5 0.91 0.29
HDS
11.25 0.36 0.95
13.75 0.59 0.74
14.25 0.77 0.58
14.75 0.77 0.48
15.25 0.82 0.34
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Discussion
This study examined the validity of the MoCA and HDS in relation to classification of 
cognitive impairment using both the Frascati and CIND criteria in a Dutch group of 
HIV-infected patients. With respect to discriminating patients with and without 
cognitive impairments classified using both the Frascati and the CIND criteria, the 
AUCs for both the MoCA and the HDS were statistically significant. Cut-off scores 
with both good sensitivity accompanied with a respectable specificity could not be 
determined, however. Furthermore, the AUCs for the MoCA and the HDS did not 
differ significantly regardless of the scoring criteria. 
 The proportion of HIV-infected individuals with cognitive impairments identified 
using the Frascati criteria (41.1%) is similar to previous estimates of 33.3% and 52% 
reported by Tozzi et al. and Heaton et al. respectively [1,46]. When the more stringent 
CIND criteria are used, a much lower proportion of the patients was classified as 
being cognitively impaired (23.2%). Using the current Frascati guidelines, the milder 
forms of HAND (MND and ANI) are defined by a performance 1 SD below the mean 
of normative scores in at least two domains. As mentioned previously about 16% of 
the normal population will by definition perform worse than 1 SD below the mean on 
a given test. In other words, around 16% of a normal population will be classified as 
impaired when the Frascati criteria are used, which is an unacceptable false positive 
rate (that is, 2-5% percent is generally considered acceptable) [22]. Overestimation 
of the prevalence of HAND due to liberal classification criteria obscures the actual 
extent of cognitive deficits in HIV-infected individuals [4]. Therefore, using more 
stringent criteria to determine cognitive impairment must be recommended. 
Alternative criteria to determine cognitive impairment in HIV-infected patients, first 
suggested in this study, are the CIND criteria. These criteria define impairment as an 
average performance >1 on the tasks in a cognitive domain. To obtain a score of >1 
on a given domain, at least one of the tasks in that domain has to be severely 
impaired. The CIND criteria are therefore more stringent then the Frascati criteria. 
These might be used as an alternative to the Frascati criteria in classifying HIV-related 
neurocognitive impairment.
 As noted previously, for both the MoCA and HDS good sensitivity and specificity 
could not be found in distinguishing cognitively impaired from cognitively unimpaired 
patients. The sensitivity for both the MoCA and HDS was particularly low for the 
recommended cut-off scores when either the Frascati or CIND criteria were used to 
classify cognitive impairment. The sensitivity increased slightly when the thresholds 
for the MoCA and the HDS were raised, yet their specificity remained low, indicating 
a high risk of false-positive results. The current findings for the HDS are in line with 
previous studies who demonstrated poor prognostic values using the HDS to detect 
mild impairment in HIV-infected patients [7,10,12]. This screening tool was originally 
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developed to detect HIV-associated dementia, and the performance characteristics 
to detect severe forms of cognitive impairment are modest to good [47]. Morgan et al. 
showed that performance could be improved by adjusting for age and education, but 
the sensitivity remains modest (0.70) even after adjustment [48]. To our knowledge, 
there are only a few studies that extensively investigated the validity of the MoCA in 
HIV-infected patients. Recent research of Overton et al. who also used extensive 
neuro psychological testing found somewhat higher sensitivity scores for the MoCA 
compared to the current study, but with comparable specificity levels [7]. Another 
recent study by Milanini et al. found higher sensitivity and specificity levels than the 
current study, but investigated an older population of patients over 60 years [21]. A 
study by Hasbun et al. showed moderate diagnostic accuracy for the MoCA (sensitivity 
85%, specificity 40%) [20]. In contrast to the current study, the latter investigated 
ART-naïve HIV-infected patients with high viral loads and high levels of co-morbitities 
(hepatitis B and C), active drug use, depression and unemployment. Koski et al. 
reported that the MoCA adequately measures cognitive ability as a global construct 
using Rasch analyses, but showed poorer precision for measuring patients with 
higher cognitive ability [6]. That is, half of the MoCA items were too easy for their 
high-functioning sample, resulting in ceiling performance. These items therefore 
contributed little to the measurement of overall cognitive ability in this group. 
 Regardless of the criteria used to classify the neuropsychological performance, 
milder forms of cognitive impairments continue to exist in a substantial amount of 
HIV-infected patients. Given the impact that these impairments may have on daily 
functioning and quality of life, the need for effective screening instruments to identify 
these patients remains high. Our study shows that simple tools developed for 
HIV-associated dementia are suboptimal in discriminating current HIV-infected 
populations. More comprehensive screening tools, like the MoCA, show mixed 
results in the literature. In our study, the validity of the MoCA was about similar to that 
of the HDS, but respectable sensitivity and specificity of this screening tool has been 
demonstrated for other patient groups. Sensitivity levels could be improved when the 
cut-off scores were increased, but the specificity levels remained low. A high 
sensitivity might be preferred in the clinical practice, however, combined with a low 
specificity the risk of identifying patients without cognitive impairments as ‘impaired’ 
is high. As a result, these tools are not recommended for use in the diagnostic 
process.
 Our study was the first to investigate the validity of the MoCA in comparison with 
the HDS. Furthermore, unlike previous studies that have investigated the validity of 
MoCA and the HDS in HIV-infected patients, ours is the first that used both the 
Frascati and CIND criteria to classify cognitive impairment. Strengths of the study are 
the use of an extensive neuropsychological test battery in comparison to the short 
cognitive screening tools, and the application of a symptom validity test. In order to 
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obtain monetary compensation and/or service benefits, some patients might feign or 
exaggerate their neuropsychological deficits [44]. Symptom validity tests are designed to 
be passable for all but the most severely impaired patients, given that the participant 
has provided adequate mental effort in the task. Also, this study had several limitations. 
Only HIV-infected patients who were on cART and were virologically suppressed for 
at least one year were included. These inclusion criteria were deliberately set to 
reduce the influence of other potentially confounding factors that may be present in 
uncontrolled HIV-infected patients, such as hepatitis B or C, syphilis or malignancy. 
While, our sample is representative for the majority of HIV-infected patients in the 
Netherlands, to investigate detailed performance characteristics of cognitive screening 
instruments, a more heterogeneous group of patients with respect to severity of 
cognitive deficits might show better results [49]. Secondly, although all patients were 
living independently at home and none fulfilled the criteria for dementia, we did not 
formally assess activities of daily living. 
 In sum, our study showed moderate sensitivity combined with poor specificity in 
detecting cognitive impairment with the MoCA and the HDS in HIV-infected patients, 
using both the widely applied Frascati criteria and the more stringent CIND criteria 
to classify cognitive impairment. On the basis of the present results we cannot 
recommend these tools for the assessment of HIV-associated cognitive impairment. 
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Abstract
Despite long-term successful treatment with cART, impairments in cognitive 
functioning are still being reported in HIV-infected patients. Since changes in cognitive 
function may be preceded by subtle changes in brain function, neuroimaging 
techniques, such as resting-state functional magnetic resonance imaging (rs-fMRI) 
have become useful tools in assessing HIV-associated abnormalities in the brain. 
The purpose of the current study was to examine the extent to which HIV infection in 
virologically suppressed patients is associated with disruptions in subcortical regions 
of the brain in comparison to a matched HIV-negative control group. The sample 
consisted of 72 patients and 39 controls included between January 2012 and January 
2014. Resting state functional connectivity was determined between fourteen regions- 
of-interest (ROI): the left and right nucleus accumbens, amygdala, caudate nucleus, 
hippocampus, putamen, pallidum and thalamus. A Bayesian method was used to 
estimate resting-state functional connectivity, quantified in terms of partial correlations. 
Both groups showed the strongest partial correlations between the left and right 
caudate nucleus and the left and right thalamus. However, no differences between 
the HIV patients and controls were found between the posterior expected network 
densities (control network density = 0.26, SD = 0.05, patient network density = 0.26, 
SD = 0.04, p=0.58). The results of the current study show that HIV does not affect 
subcortical connectivity in virologically controlled patients who are otherwise healthy.
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Background
The potential effects of human immunodeficiency virus (HIV) infection on the brain 
remain a major concern in the combination anti-retroviral therapy (cART) era, as 
impairments in cognitive functioning are still being reported in HIV-infected patients, 
despite long-term successful treatment [1-5]. Cognitive functioning is commonly 
assessed by neuropsychological testing. However, changes in cognitive function 
may be preceded by subtle changes in brain function. Neuroimaging techniques, 
such as resting-state functional magnetic resonance imaging (rs-fMRI) have become 
useful tools in assessing HIV-associated abnormalities in the brain. Rs-fMRI is a 
method that is used to evaluate the intrinsic temporal covariation of the blood- 
oxygen-level dependent (BOLD) signal acquired when a participant is not performing 
an explicit task. Using this technique, Thomas et al. investigated five functional brain 
networks including the default mode, dorsal attention, salience, executive control and 
sensorimotor networks in HIV-infected patients [6]. Lower intra-network correlations 
were found in the default mode and control and salience networks compared to 
HIV-negative controls. However, a study by Wang et al., investigating rs-fMRI networks 
in HIV-infected patients within their first year of HIV infection, only reported impaired 
functional connectivity in the lateral occipital cortex network [7]. No differences were 
reported in other resting-state networks, including the default mode network and 
executive control. Another study used rs-fMRI to investigate the frontostriatal network 
and found that HIV status and cognitive impairment were associated with a lower 
connectivity between the dorsal caudate and the dorsolateral prefrontal cortex [8]. 
Also, Ortega et al. showed that HIV-infected patients had lower functional connectivity 
between the striatum and the default mode network and ventral attention network 
compared to HIV-negative controls, with HIV-infected patients on cART showing 
higher connectivity between these networks than patients not on cART [9]. Thames 
et al. found increased activation in basal ganglia structures (e.g. the putamen and 
caudate) in HIV-infected patients during a phonemic fluency task [10]. Furthermore, 
alterations have been demonstrated in various networks, such as the default mode, 
salience network and frontal and motor networks in older HIV-infected patients 
[6,11,12]. To summarize, all studies mentioned above investigated frontal areas, for 
example, the executive control network, fronto-striatal network, and the frontal 
subcortical network. Some, but not all studies also examined the default mode 
network and sensorimotor areas [e.g. 6,7,9]. Abnormalities in the default mode 
network are reported in several studies [6,9], but not in patients within their first year 
of infection [7]. 
 The most consistent finding in previous functional connectivity studies on HIV is 
that differences are found between HIV-infected patients and healthy controls in 
executive control networks [6,8-10]. However, previous resting-state fMRI studies 
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focused exclusively on cortical and cortico-subcortical functional connectivity. So far, 
functional connectivity between subcortical structures, especially the basal ganglia, 
hippocampus, amygdala and thalamus, has not been studied. This is relevant, as 
structural abnormalities in these brain regions were found in HIV-infected patients in 
some but not all studies [5,13-15]. Potentially, functional connectivity measures may 
be more sensitive to HIV-related abnormalities, which can be hypothesized to be 
small especially in successfully treated HIV-infected patients, and as such complement 
structural neuroimaging findings [16]. 
 Also, few rs-fMRI studies only included HIV-infected patients on stable cART. 
Ortega et al.  differentiated their results into three groups: a HIV infected group on 
cART, a patient group not on cART and a control group [9]. Thomas et al. controlled 
for the effect of treatment (treatment did not have an effect on functional connectivity 
in their study) [6]. The inclusion in Thames et al. was limited to patients on cART, but 
they investigated subcortical connectivity only in a small study sample (12 HIV- and 
16 HIV+ patients) and only in relation to a very specific cognitive task (i.e., phonemic 
fluency) [10]. Since most current HIV patients in the Western world are being treated 
with cART, studies focusing on virologically suppressed HIV patients increase the 
external validity of the results. 
 Hence, the purpose of the current study was to examine the extent to which HIV 
infection in virologically suppressed patients on cART is associated with disruptions 
in specific subcortical regions of the brain in comparison to a matched HIV-negative 
control group. Structures of the basal ganglia (caudaute nucleus, putamen, nucleus 
accumbens and ventral pallidum), the hippocampus, amygdala and thalamus were 
analyzed with a new algorithm based on a sensitive Bayesian method to estimate 
resting-state functional connectivity.
Methods
Participants
Participants who underwent MR examination were selected from the original cohort 
of the Art-NeCo study, a prospective Dutch cohort study on NeuroCognition in 
HIV-infected patients on long term effective cART [5]. Consecutive patients were 
recruited through their treating physicians at the participating centers, that is, 
Radboud University Medical Center in Nijmegen and the Rijnstate Hospital Arnhem. 
For inclusion, HIV-infected patients had to be on cART for at least one year with an 
HIVRNA in plasma <20 copies/ml for at least one year. Exclusion criteria for the 
patient group included active opportunistic infections, pregnancy, malignancy or 
neurosyphilis. Healthy HIV-negative control participants were matched on age, sex 
and educational level. Both patients and controls had to be between 18 and 70 years 
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of age and fluent in Dutch language. Exclusion criteria for both patients and controls 
were current recreational drug or alcohol abuse, and a history of psychiatric or 
neurological disorder (unrelated to HIV infection in the patient group). HIV-1 status of 
patients was determined by enzyme-linked immunosorbent assays (ELISA) and a 
Western Blot confirmatory test, and with a rapid HIV test in healthy controls. Medical 
ethical approval for this study was obtained from the Medical Review Ethics 
Committee region Arnhem-Nijmegen (CMO #2011/267) and written informed 
consent was obtained from all participants. 
 Rs-fMRI data were acquired from 87 HIV-infected patients and 42 matched 
controls between January 2012 and January 2014. Fifteen patients and 3 controls 
were removed from analyses; two patients due to medical reasons unrelated to their 
HIV status, one due to enlarged ventricles secondary to atrophy and periventricular 
white-matter lesions, resulting in problems during registration and with FIRST, and 12 
because of poor image quality resulting in low contrast in subcortical regions which 
was unrelated to HIV-infection. One control was removed from analyses due to 
scanner artifacts and two due to poor image quality resulting in low contrast in 
subcortical regions. All scans were visually screened by two radiologists (SCS and 
BJ) for relevant clinical abnormalities. Also, all processed scans were visually 
checked for errors in the preprocessing stages. The total sample therefore consisted 
of 72 patients and 39 controls. Note that based on neurocognitive testing, 27 of these 
patients fulfilled the criteria for asymptomatic neurocognitive impairment and 4 for mild 
neurocognitive disorder. None of the patients fulfilled the criteria for HIV-associated 
dementia.
Imaging methods
MR examinations were performed on a 3T Magnetom Trio scanner (Siemens, 
Erlangen, Germany). Whole-head structural MR images were acquired with a 3D 
T1-weighted MP-RAGE sequence (inversion time (TI) = 1000 ms, repetition time (TR) 
= 2300 ms, echo time (TE) = 4.71 ms, 12° flip-angle, field of view (FOV) = 256 mm, 
192 sagittal slices, slice thickness = 1 mm, voxel-size=1 x 1 x 1 mm3). Resting state 
data were acquired using a gradient-echo planar imaging (EPI) sequence (TR = 
2380 ms, TE = 30 ms, flip angle (FA) = 90°, 41 slices, 64 × 64 matrix, voxel size = 
3.5 × 3.5 × 3 mm3, 110 volumes, Field of view (FoV) = 224 mm). All participants were 
scanned on the same scanner and were instructed to close their eyes, think of nothing 
in particular, and relax while avoiding falling asleep. 
Data preprocessing
The MRI datasets were preprocessed using FSL 5.0 using default settings unless 
noted otherwise. Structural scans were processed with FAST to obtain an estimate of, 
and correct for, the bias field [17]. Brain extraction was performed on the corrected 
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images using BET, the output of which was processed again with FAST, this time to 
perform segmentation into white matter, gray matter and cerebrospinal fluid (CSF) 
[18]. Subcortical regions were parcellated using FIRST [19]. Functional scans were 
motion corrected using MCFLIRT and linearly registered to the T1 image using FLIRT 
[20]. Mean white matter and CSF signals, combined with the estimated motion and 
temporal derivatives thereof, were regressed out using FEAT. Finally, data were high- 
pass filtered with a cut-off of 100 Hz.
Data analysis 
Functional connectivity was determined between fourteen regions of interest (ROI): 
the left and right nucleus accumbens, amygdala, striatum, hippocampus, pallidum 
and thalamus, to investigate subcortical resting-state functional connectivity. A Bayesian 
method was used to estimate connectivity, quantified in terms of partial correlations 
[21]. This approach determines the probability distribution over all different network 
structures that are supported by the data, rather than estimating only the most 
probable network. The method is able to find unbiased functional connectivity and 
has been demonstrated to outperform state-of-the-art alternatives such as the 
graphical lasso in recovery of functional connectivity [21,22]. The method assumes 
that partial correlations, representing the strength of direct functional interactions, 
presuppose a skeleton of conditional independencies. That is, functional connectivity 
is represented by a binary network indicating which regions are connected, in addition 
to a weighted network of partial correlations that indicate the strength of connections. 
As partial correlations only need to be estimated for conditionally dependent pairs of 
ROI, the method reduces the effective number of parameters to be estimated without 
underestimating connection strengths. This is particularly effective when the number 
of samples is limited compared to the number of connections that must be estimated 
[21].
 The posterior distribution of functional connectivity (both the binary skeleton and 
the partial correlations) was estimated for each subject, using a Markov chain Monte 
Carlo (MCMC) technique. Subsequently, the posterior expectation of network density 
(of the binary graph) and the partial correlation strengths were computed to summarize 
the results per subject. 
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Results
The groups were well balanced for age, sex and education level (see Table 1). 
Partial correlations
The connectivity estimates, quantified in terms of partial correlations, are shown as 
adjacency matrices in Figure 1, for both the healthy control group and the HIV-infected 
patients. In these plots, each element of the matrix indicates the expected partial 
correlation between the row-ROI and the column-ROI, averaged over all participants 
per group. These partial correlations were in the range [-0.04, 0.55] for the control 
group and in the range [-0.05, 0.50] for the patient group. As the matrices indicate, 
both groups show the strongest partial correlations between the homotopic regions 
in the different hemispheres, as indicated by the diagonals in the upper right and 
lower left quadrants. The strongest partial correlations in both groups are found 
between the left and right caudate nucleus (0.41, SD = 0.01 for the control group and 
0.36, SD = 0.01 for the patient group) and the left and right thalamus (0.55, SD = 0.01 
for the control group and 0.50, SD = 0.01 for the patient group). However, no 
substantial differences appear to be present between the two groups upon visual 
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Table 1   Demographic variables for patients and controls.
Characteristic Patients (N=72 ) Controls (N=39)
Age (years) [mean (range, SD)]  48.8 (26-70, 9.3)  52.6 (28-68, 10.7)
Sex 61 (84.7%) men 
MSM: 55 (90.2%)
11 (15.3%) women
31 (79.5%) men
 MSM: 8 (25.8%)
8 (20.5%) women
Nadir CD4 cell count (cells/µL) [mean (IQR)] 213 (90-310) n.a.
Duration HIV-infection (years) [mean (IQR, SD)] 9.4 (4.4-14.6, 6.4) n.a.
Duration cART treatment (years) [mean (IQR, SD)] 7.8 (3.1-12.8, 5.6) n.a.
Regular alcohol use1 17 (23.6%) 20 (51.3%)
Regular drug use2  7 (9.6%) 3 (7.7%)
Education level [median (range)]3 6 (2-7)  6 (3-7)
Estimated IQ [mean (SD)] 98*(14.5)  104 (14.0)
1Regular alcohol use is use of alcohol for three or more times a week or binge drinking on two subsequent 
days. 2Regular drug use is use of a drug for four times or more times a month. 3Education level was 
recorded using seven categories based on the Dutch educational system, which can be related to the 
Anglo-Saxon system using years of education: 1:1-5 years, 2:6 years, 3:7-8 years, 4:7-9 years, 5:7-10 
years, 6:7-17 years and 7: >18 years. *p < 0.05. n.a. = not applicable. MSM = Men who have sex with 
men.
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inspection of the matrices. This was confirmed by computing the posterior expected 
network densities for all participants per group, between which, again, no significant 
difference was found (control network density = 0.26, SD = 0.05, patient network 
density = 0.26, SD = 0.04, p=0.58, 2-tailed t-test) (Figure 2). 
Figure 1   Functional connectivity estimates for the healthy control group and 
HIV-infected patients.
Figure 2   Network density for the healthy control group and HIV-infected patients.
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Discussion
This is the first study that has used a new algorithm based on a sensitive Bayesian 
method to estimate resting-state functional connectivity between fourteen subcortical 
regions of interest in HIV-infected patients compared to a well-matched healthy 
control group. Our data show the strongest partial correlations between the homotopic 
regions in the two hemispheres and particularly between the left and right caudate 
and the left and right thalamus. However, no differences in the posterior expected 
network densities were found between the HIV-infected patients and the healthy 
control group. 
 The results of the current study are not in agreement with earlier rs-fMRI findings 
showing reduced connectivity between various brain networks in HIV-infected 
patients compared to healthy controls, as we did not find any differences in subcortical 
connectivity between patients and controls [6-9]. One important difference between 
the current study and the earlier studies is that in our study only patients on cART and 
with long term undetectable HIVRNA (at least one year) were included, while in the 
other studies more heterogeneous HIV groups were used. Furthermore, previous 
studies focused on subcortical-cortical connectivity, while in the current study 
subcortical connectivity was investigated. Volumetric subcortical atrophy has been 
reported in earlier studies [23,24], also in HIV-infected patients with well-controlled 
immune status and viral replication [25]. Moreover, Thames et al. showed increased 
activation in the putamen and caudate nucleus during a lexical retrieval task [10]. 
 Our findings are in line with the finding of Ortega et al., who showed that patients 
on cART had higher functional connections within the ventral attention network than 
patients who were not on cART [9]. Also, their patients on cART had similar functional 
connections in the default mode network as the HIV negative control group. 
Successful cART has been shown to reduce glial activation as well as inflammation 
caused by HIV infection [26,27]. Moreover, cART decreases HIV viral load in the 
central nervous system (CNS) and reduces the synapto-dendritic damage that 
occurs by HIV [28,29]. Therefore, as cART reduces inflammation in the CNS it may 
improve synaptic communication, which may in turn lead to normalized connectivity 
in various resting-state networks. 
 One could argue that a relatively small number of samples (110) were acquired 
for the resting-state fMRI scan in relation to the number of estimated connections (91) 
in the current study, limiting the signal-to-noise (SNR) ratio. Clearly, more volumes result 
in a better SNR-ratio, which increases the likelihood of detecting small differences 
between groups. Therefore, it remains to be investigated whether our conclusions are 
maintained in the face of larger sample sizes. Also, our study sample consisted of 
patients and controls in a broad age range (i.e., 18-70). Although the age range was 
comparable for patients and controls, future studies should specifically examine the 
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role of age and functional connectivity in HIV. That is, while aging in HIV may be an 
independent factor [6], others reported interactions between aging and HIV-related 
changes in functional connectivity [11]. With our current sample, stratification into 
multiple age groups would have resulted in insufficient statistical power due to small 
subgroups. Also, the heterogeneity with respect to duration of the HIV infection, cART 
treatment duration and CD4 count should be examined using larger samples, as 
these disease markers are associated with disruptions in resting state functional 
connectivity [12]. The Bayesian approach of the present study, however, requires 
stratified groups to take these potentially confounding factors into account.
 Previous results from the Art-NeCo study showed small but significant volume 
differences in the thalamus and total brain volume between HIV-infected patients 
and controls, with the patient group showing smaller volumes. In that study, no effect 
of HIV infection was found on overall cognitive performance. In the present study 
no differences in resting-state subcortical connectivity were found between the 
HIV-infected patients and the healthy control group, which adds to recent findings 
showing only small cognitive decrements and neural changes in successfully treated 
HIV-infected patients on long-term cART who are otherwise healthy [5,30,31]. However, 
this result should be interpreted with some caution, as we used a novel algorithm to 
analyze our data. Validation of our findings is needed, using larger samples in order 
to control for various confounding factors like age and disease variables.
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Introduction
The aim of this thesis was to investigate cognitive performance, brain functioning and 
wellbeing in effectively treated HIV-infected patients. More specifically, cognitive 
functioning over a one-year period of time was measured with a comprehensive 
neuro psychological assessment. Also the validity of two short cognitive screening tools 
was investigated. Subjective wellbeing was assessed with four self-report questionnaires. 
Brain functioning was examined with both structural and resting state functional 
MRI measures. In this last chapter, an overview of the main results and conclusions 
will be presented. Also, strengths, limitations and implications for future research will 
be discussed. Finally, recommendations for clinical practice will be provided. 
Main findings
The main impetus for the current thesis project was given by a pilot study about 
cognitive functioning, symptom validity and psychological wellbeing in a first 
subgroup of 30 consecutive HIV-infected patients, both treated and untreated, and 
30 matched healthy control participants. Only patients without active opportunistic 
infections, pregnancy, malignancy and neurosyphilis were included. Both patients 
and controls with a current drug or alcohol addiction and/or a history of psychiatric or 
neurological disorder were excluded (chapter 2). The aim was to examine the nature 
and extent of deficits in cognitive performance and to explore the relation between 
cognitive functioning and psychological wellbeing while taking symptom validity into 
account. An extensive neuropsychological test battery was administered, covering 
eight main cognitive domains (verbal fluency, speed of information processing, 
learning, memory, executive functioning, attention/working memory, motor function 
and visuoconstruction). Also, the Revised Dutch version of the Symptom Checklist 
(SCL-90-R) [1] and the Amsterdam Short Term Memory Test (ASTM) [2] were 
administered. A small number of both patients and controls performed below the 
cut-off of the symptom validity test indicating suboptimal cognitive effort. These 
individuals were removed from subsequent analyses. In this sample, HIV-infected 
patients showed a worse overall cognitive performance in comparison to the healthy 
controls. Further analyses showed that this effect was mainly due to a worse 
performance in the cognitive domain working memory, whereas no differences were 
found in any of the other cognitive domains. This lower performance on the domain 
working memory remained even after excluding the untreated patients from the 
analyses. Furthermore, patients reported more anxiety, depressive, cognitive, 
interpersonal and irritability related complaints. These complaints were not related to 
cognitive performance. 
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These pilot data provided evidence that that deficiencies in cognitive performance 
and lower levels of psychological wellbeing might be a problem in HIV-infected 
patients, even in the cART era. These results confirmed the need for further controlled 
empirical study in a larger group of participants. 
 Chapters 3 and 4 describe the baseline and follow-up studies on cognitive 
functioning and wellbeing in a group of 95 successfully treated HIV-infected patients 
on long-term cART. This group was compared with a control group consisting of 55 
healthy participants matched on age, sex and education. Largely the same neuro-
psychological test battery as in the pilot study was administered. Assessment of 
psychological wellbeing was extended at baseline with the Dutch version of the 
Hospital Anxiety and Depression Scale (HADS) [3,4], the Dutch version of the 
Cognitive Failures Questionnaire (CFQ) [5,6] and the Medical  Outcome Study-HIV 
Health Survey (MOS-HIV) [7]. In addition to cognitive assessment and wellbeing, 
brain volumetric measures were examined at baseline both in the patients and in the 
controls. Results demonstrated between-group differences on the cognitive domains 
speed of information processing and motor function. Although these differences 
were statistically significant, the nature of the decrements was mild.
 Furthermore, significantly lower levels of psychological wellbeing and self- 
reported quality of life were found in HIV-infected patients in comparison to the healthy 
controls. No differences were found on severe anxiety or depressive symptoms. 
Again, the differences in psychological wellbeing and self-reported quality of life were 
small, with individual scores being often below clinical cut-off points. A weak yet 
significant correlation was found between self-reported measures of wellbeing and 
the cognitive domains of motor function and speed of information processing. 
Interestingly, no differences were found between these cognitive domains and 
subjective reports of cognitive functioning. 
 With respect to the structural MRI results, small but statistically significant 
differences in volumes were found for the total brain and the thalamus, with the 
patient group showing smaller volumes than the controls. We concluded that the 
decrements found in this study were again very mild, showing that HIV infection in 
and of itself has a relatively minor impact on cognitive functioning, wellbeing and the 
brain in long-term successfully treated HIV-infected patients. 
 At one-year follow-up, the patients, again, performed worse on the cognitive 
domain speed of information processing (chapter 4). Interaction effects were found 
for the domains verbal fluency and executive functioning over time. No group 
difference was found for the domain verbal fluency at baseline, while the patients 
performed worse than the controls at follow-up. For the domain executive function, 
no group difference was found at follow-up, but the patients performed worse than 
the controls at baseline. Individual analyses using Reliable Change Indices (RCIs) 
showed that cognitive decline, defined as showing a reliable decline on at least one 
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cognitive domain, was present in 13.4% of the patients. Patients who cognitively 
declined reported more psychological complaints and more often used recreational 
drugs. However, the ‘’decliners’’ did not differ from the non-decliners on any of the 
HIV disease-related variables. We concluded that cognitive decline over a one-year 
period is small, as only a decline in one of the eight cognitive domains was found at 
group level and at the individual level only a small subset of patients (13.4%) showed 
cognitive decline. 
 In chapter 5, the validity of two short cognitive screening tools, the Montreal 
Cognitive Assessment (MoCA) and the HIV Dementia Scale (HDS) in detecting 
cognitive impairment was investigated. Cognitive impairment was measured with the 
same gold-standard neuropsychological test battery as in the studies discussed in 
chapter 3 and 4. Impairment was classified with two well-known classification protocols, 
namely the Frascati criteria and the ‘cognitive impairment, no dementia’ (CIND) 
criteria [8,9]. The Frascati criteria are widely used in HIV research, but concerns have 
been raised that these criteria may be too liberal in classifying a person as ‘cognitively 
impaired’ resulting in an unacceptably high number of false positive outcomes [10]. 
Therefore, we have used the CIND criteria, which are more stringent, in addition. The 
diagnostic accuracy (i.e., the areas under the curve (AUCs)) of the MoCA and HDS 
were statistically significant, with cognitive impairment classified with either the 
Frascati or the CIND criteria. No cut-off scores with both a good sensitivity and a high 
specificity could be found. The AUCs for the MoCA and the HDS did not differ 
significantly, indicating that the one screening tool was not better than the other in 
detecting cognitive impairment. Furthermore, the proportion of HIV-infected individuals 
classified as cognitively impaired was higher when using the Frascati criteria (41.1%) 
than using the CIND criteria (23.2%), stressing the importance of considering other, 
more stringent criteria to classify HIV-related cognitive impairment.
 The study described in chapter 6 evaluated functional connectivity through 
resting-state fMRI (rs-fMRI) in subcortical areas (the basal ganglia, hippocampus, 
amygdala, and thalamus) of the brain with a new algorithm based on a sensitive 
Bayesian method. Using this approach, we were able to determine the probability 
distribution over all different network structures that are supported by data, rather 
than estimating only the most probable network. The results showed that the 
strongest partial correlations in both the patient and the control group were between 
the homotopic regions in the different hemispheres. However, no statistical differences 
in rs-fMRI in the subcortical areas were found between patients and controls. We 
concluded that this finding is line with our previous results described in chapter 3 and 
other recent findings showing only small [11,12] or even no [13] cognitive deficits and 
neural changes in successfully treated HIV-infected patients. 
 To summarize, comprehensive neuropsychological assessment of cognitive 
functioning showed that decrements in HIV-infected patients are small. Cognitive decline 
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at an individual level was only present in a small subset of patients. The assessed short 
cognitive screening tools HDS and MoCA failed to detect these small decrements in 
our HIV-infected patient sample. Also, significantly lower levels of psychological 
wellbeing and quality of life were reported by HIV-infected patients in comparison to 
the healthy controls, yet scores most often stayed above the clinical cut-off values. 
Lastly, small differences in overall brain volume and the thalamus were found between 
patients and controls, with patients showing smaller volumes. In the following section 
the strengths, limitations and implications for future research will be discussed. 
Strengths, limitations and future directions 
The study presented in this thesis investigated cognitive functioning, wellbeing and 
brain correlates in long-term successfully treated HIV-infected patients in comparison 
to a matched healthy control group. Importantly, most previous studies have 
investigated these factors mainly in isolation, focusing on just one or two of these 
research fields. A major strength of the research presented in this thesis is the 
inclusion of a healthy control group matched on age, sex and education level, rather 
than relying on available normative data. That is, the quality of normative data is often 
mixed and lifestyle factors of normative samples are typically poorly documented. 
This is especially the case with Dutch norms, as the Dutch-language domain is small. 
As a result, normative data do not always provide adequate adjustments for age, sex, 
lifestyle factors and education level. Therefore, a matched control group has the 
advantage of being able to validly interpret the performance of the patient group. 
Furthermore, studies on cognitive functioning in HIV-infected patients including a 
control group and using normative data were lacking in the Netherlands. Another 
strength of the study design is the inclusion of a symptom validity test, which is not 
often incorporated in previous studies on HIV. The possibility that a small subset of 
patients might exaggerate cognitive symptoms is important to take into account [14]. 
Excluding participants who performed below the cut-off on a symptom validity test 
due to suboptimal mental effort from analyses increases the validity of the results. In 
our study, suboptimal performance turned out to be a minor problem as only a small 
number of both patients and controls performed below the cut-off. However, in other 
study populations suboptimal performance may be more common which, as a 
consequence, might impair the study results. This may be the case in countries 
where there is limited access to health care or where the costs of health care are high. 
In such circumstances patients might exaggerate or even feign cognitive deficits in 
order to obtain some form of compensation, such as health service benefits or 
treatment options that are otherwise inaccessible. Therefore, validity testing should 
be considered in future research. 
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 With regard to patient selection, individuals with psychiatric disorders like depression 
were excluded from the study. One could argue that excluding patients with a 
depressive disorder resulted in a selection bias, as a large subgroup of patients was 
not taken into account. That is, the prevalence of depressive disorder in HIV-infected 
patients is higher than in the general population and is estimated to be as high as 
40% [15]. While this is a reasonable concern, depressive symptoms in itself can have 
a major influence on cognitive performance which makes it almost impossible to 
differentiate the effect of HIV infection from depression on cognitive performance. 
 Also, the studies of this thesis only included patients who were successfully 
treated with cART. That is, patients had to be on cART treatment for at least one year, 
with HIVRNA in plasma less than 20 copies/ml also for at least one year. These criteria 
were set in order to rule out the influence of other potentially confounding factors that 
may be present in uncontrolled HIV-infected patients, such as hepatitis B or C, 
syphilis, or malignancy. Another reason for these inclusion criteria is that the majority 
of HIV-infected patients in the Netherlands fulfill these criteria. Therefore the study 
population is representative for the majority of the HIV-infected patient population in 
the Netherlands [16]. However, as a consequence the external validity of the results 
is limited to the Western world, in which people have access to high-quality health 
care and treatment medication. 
 With respect to the reported numbers of patients with HAND,  great heterogeneity 
exists in study populations investigating cognitive functioning with respect to factors 
like treatment status, disease stage, comorbidities, age, cognitive- and psychological 
complaints. This resulted in large variability in the reported estimates of patients with 
cognitive impairments, ranging from 18% to 69% [12,17-23]. Another factor explaining 
the mixed results of the reported estimates of cognitive impairment may be the criteria 
that are used to classify cognitive impairment. Two aspects are relevant here. First, 
various studies have used different criteria. That is, the updated Frascati criteria 
(updated in 2007) are often, but not always used [8]. Many studies use other criteria 
to classify cognitive impairment [11,13,19,22]. Different criteria may lead to variable 
estimates of cognitive impairment. Second, it can be argued that the Frascati criteria 
are too lenient, especially with respect to the mildest form of HAND, asymptomatic 
neurocognitive impairment (ANI).  ANI is defined as a performance of 1 standard 
deviation below the mean of normative scores in at least two cognitive domains in the 
absence of impairments in activities of daily living. As Gisslén et al. pointed out, given 
the normal distribution, 15.9% of any population, including healthy individuals, 
perform worse than 1 standard deviation (SD) below the normative mean on any 
given test [10]. Using these criteria to classify patients with ANI will inevitably result in 
an unacceptably high false positive rate. Another problem with the Frascati criteria is 
that an abnormal score on a single test is sufficient to classify a participants 
performance in a particular cognitive domain as impaired. Assessment of multiple 
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tests to classify a cognitive domain as impaired is needed to reduce the chance of 
falsely drawing the conclusion that a particular result is abnormal. However, assessing 
numerous tests classified with the Frascati criteria will also result in problems with 
multiple testing, as the chance of finding impairments increases with 0.159 with each 
additional test. In other words, the more tests used the greater the chance of being 
classified as impaired if no adjustment for multiple testing is performed. Due to these 
shortcomings, the Frascati criteria will inevitably result in false positive classifications, 
leading to an overestimation of the true HAND prevalence. Therefore a major revision 
of these criteria is recommended and alternative criteria to classify HAND should 
be considered. For example, Su et al. suggested multivariate normative comparison, 
a statistical method that is a multivariate version of Student’s t-test for one sample, 
as an alternative to the Frascati criteria to classify cognitive impairment [11]. In the studies 
presented in this thesis, we proposed the CIND criteria as an alternative. The CIND 
criteria are more stringent, as they require at least one of the test scores in a cognitive 
domain to be lower than 1 SD below normative means. Performance on each test is 
rated as within the normal range (0), below average (1) or impaired (2). A score 
between -1 SD and 1 SD was defined as normal performance, a score between -1 SD 
and -1.65 SD as mildly impaired and a score below -1.65 SD was classified as 
impaired. Using the CIND criteria, a cognitive domain is classified as impaired when 
the average rating of tests in that domain was >1 [see 9].
 Another strength is the use of Reliable Change Indices (RCIs) to measure reliable 
individual decline. Only a few other studies have used a statistical method to classify 
individual significant cognitive change [24-26]. In these studies a combination of both 
virologically suppressed and unsuppressed patients was included. Ours is the first 
study to use a statistical method to measure cognitive decline in a group that 
consisted only of longitudinally suppressed HIV-infected patients.
 A limitation is the follow-up interval of one year in the study on cognitive change 
described in chapter 4. A one-year period is relatively short, especially in a study 
sample consisting only of patients on stable cART treatment in whom the cognitive 
decrements are very mild. Therefore future studies in virologically suppressed 
patients with longer follow-up periods are needed. This is especially important in the 
cART era, as the extended life expectancy might result in an increased prevalence of 
cognitive deficits. Cognitive efficiency decreases with age, and advancing age is an 
important risk factor for the development of neurodegenerative disorders like 
dementia. However, the degree to which aging and HIV infection interact to accelerate 
cognitive deterioration is not completely understood. In their review Wendelken and 
Valcour concluded that under the age of 60, interaction effects are not likely to be 
clinically important [27]. However, insufficient data exist to firmly draw conclusions 
about individuals over the age of 60 years. This stresses the need for longitudinal 
cohort studies that follow patients for several decades. 
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Clinical implications
As noted in the introduction many HIV-infected patients report complaints about 
memory and concentration in the consultation room. Only small differences between 
HIV-infected patients and control participants in cognitive functioning and wellbeing 
were found in the current study. The assessed cognitive screening tools lacked good 
sensitivity and specificity to detect these small decrements. Use of short cognitive 
screening tools to replace neuropsychological assessment is therefore not 
recommended, as we found that both a simple tool developed for HIV-associated 
dementia, the HDS and also a more comprehensive tool as the MoCA fail to detect 
cognitive deficits in current HIV-infected populations. Comprehensive neuropsycho-
logical assessment is still needed to detect cognitive impairment in individual 
patients. As we found no relationship between subjective cognitive complaints and 
objective cognitive performance, asking the patient about cognitive problems might 
not be a reliable representation of objective cognitive impairment. That patients’ 
perceptions of their own cognitive functioning are often unrelated to their objective 
cognitive performance is a frequently reported finding in patients with various 
conditions including HIV infection [28-32]. Therefore referral to a psychologist for 
neuropsychological assessment is recommended in order to quantify objective 
cognitive impairments when there is doubt about a patients’ cognitive functioning. 
 When a patient is referred for neuropsychological assessment we advise to not 
only focus on cognitive functioning, but also take psychological wellbeing, quality of 
life and cognitive complaints into account. Living with a chronic condition that is still 
surrounded with a lot of stigma can be a heavy burden for patients. Administration of 
validated self-report questionnaires may help guide conversations about these often 
sensitive topics. Additionally, psychological education and interventions might be 
helpful in order to gain more insight into emotional and cognitive processes and 
provide tools to deal with problems that play a role in daily functioning. 
Conclusion
The studies in this thesis focused on multiple outcomes, that is, cognitive functioning, 
neuroimaging and wellbeing, thereby providing a comprehensive overview of the 
health status in successfully treated HIV-infected patients in the Netherlands. 
Comprehensive neuropsychological assessment of cognitive functioning showed 
that decrements are small in our HIV sample. Cognitive decline at an individual level 
was only present in a small subset of patients. Short cognitive screening tools such 
as the HDS and MoCA fail to detect small decrements in successfully treated 
HIV-infected patients who are otherwise healthy. Furthermore, significantly lower 
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levels of psychological wellbeing and quality of life were reported by HIV-infected 
patients in comparison to the healthy controls, yet scores most often were above the 
clinical cut-off values. Lastly, small differences in overall brain volume and the 
thalamus were found between patients and controls, with patients showing smaller 
volumes. In general, we conclude that the impact of HIV-infection in patients on 
long-term successful treatment with cART is small. Differences on all the outcome 
measures were small and often stayed above the clinical cut-off values, which is a 
tentatively positive message for all well treated HIV-infected patients in the 
Netherlands. 
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Het humaan immunodeficiëntievirus, afgekort hiv, is een retrovirus die het immuun- 
systeem van het menselijk lichaam aanvalt. In Nederland waren in mei 2016 25.326 
mensen besmet met hiv. Hiervan zijn 18.866 personen in zorg bij een van de 26 
hiv-behandelcentra. De meerderheid van de personen in zorg in Nederland zijn 
mannen die seks hebben met mannen (62%). Daarnaast heeft 29% van de personen 
hiv opgelopen via heteroseksueel contact, 2% via intraveneus drugsgebruik, 1% via 
bloedcontact en 6% door een andere of onbekende oorzaak. 
 Omdat hiv ook de hersenen aantast kunnen er cognitieve stoornissen ontstaan, 
zeker wanneer er geen behandeling volgt. Voor de komst van effectieve medicatie 
ontwikkelden hiv-patiënten uiteindelijk de dodelijke ziekte aids, die ook gepaard gaat 
met ernstige cognitieve stoornissen (dementie), problemen in de motoriek en gedrags-
stoornissen. Door de komst van combinatie antiretrovirale therapie (cART) in 1996 
veranderde hiv van een dodelijke ziekte in een chronische ziekte. Het aantal hiv- 
patiënten dat dementie ontwikkelde nam hierdoor ook aanzienlijk af. Een overgrote 
meerderheid van de groep personen die in Nederland in zorg zijn wordt behandeld 
met cART (95%). Van deze groep wordt het virus in 93% van de personen succesvol 
onderdrukt. Ondanks succesvolle behandeling, rapporteren patiënten in de klinische 
praktijk soms nog steeds klachten zoals moeite met concentreren en geheugen-
problemen. 
 Een manier om cognitieve stoornissen vast te stellen is het uitvoeren van een 
neuropsychologisch onderzoek, waarbij cognitieve tests worden afgenomen. Hierbij 
is het belangrijk om alle belangrijke cognitieve domeinen te onderzoeken (taal, leren 
en geheugen, executieve functies, aandacht, motorische functies, snelheid van 
 informatieverwerking, en visuoconstructie). Sinds de beschikbaarheid van cART, 
zijn de cognitieve stoornissen veelal licht van aard. Daarom is het belangrijk om tests 
uit te kiezen die gevoelig genoeg zijn om kleine verschillen in cognitieve prestaties 
te meten. Een nadeel van uitgebreide cognitieve testbatterijen is dat het veel tijd kost 
om deze af te nemen. Ook kunnen deze tests alleen afgenomen en geïnterpreteerd 
worden door gekwalificeerde (klinisch) neuropsychologen. Daarom is onder zowel 
clinici als onderzoekers veel vraag naar korte screeningsinstrumenten die betrouwbaar 
en valide zijn in het vaststellen van cognitieve stoornissen. Een screeningsinstrument 
die ontwikkeld is om hiv-dementie vast te stellen is de HIV Dementia Scale (HDS). 
Dit instrument bestaat uit vier onderdelen om het geheugen, de psychomotorische 
functies, de snelheid van informatieverwerking en de visuoconstructie te meten. De HDS 
is geschikt om ernstige cognitieve stoornissen vast stellen, maar is niet gevoelig genoeg 
om lichtere vormen van cognitieve stoornissen te meten. Een ander screenings-
instrument dat mogelijk geschikt is om hiv-gerelateerde cognitieve stoornissen vast 
te stellen is de Montreal Cognitive Assessment (MoCA). Dit instrument meet acht 
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cognitieve domeinen waaronder executieve functies, geheugen, aandacht en taal. 
Dit instrument is mogelijk beter in staat dan de HDS om lichtere vormen van cognitieve 
stoornissen te detecteren. 
 In het hiv-onderzoek wordt vaak gebruik gemaakt van de zogenaamde Frascati- 
criteria om hiv-gerelateerde cognitieve problemen te classificeren. Deze aandoening 
wordt HIV-Associated Cognitive Disorder genoemd, afgekort HAND. Deze criteria 
worden gebruikt om het neuropsychologisch onderzoek of cognitieve screenings-
instrument te interpreteren. HAND is onderverdeeld in drie vormen. De lichtste vorm 
is Asymptomatic Neurocognitive Impairment (ANI), waarbij de cognitieve problemen 
minimaal zijn (ten minste 1 standaarddeviatie onder het gemiddelde) en er geen 
problemen zijn in het dagelijks functioneren. Bij de iets ernstigere vorm Mild Neuro-
cognitive Disorder (MND) zijn er ook lichte cognitieve problemen, maar gaan deze 
ook gepaard met lichte beperkingen in het dagelijks functioneren. De derde en 
ernstigste vorm van HAND is HIV-Associated Dementia (HAD). Bij HAD is er sprake 
van ernstige cognitieve afwijkingen (ten minste 2 standaarddeviaties onder het 
gemiddelde) die een grote beperking vormen in het dagelijks leven. Bij alle drie de 
vormen van HAND moet er sprake zijn van stoornissen in minstens twee cognitieve 
domeinen die niet verklaard kunnen worden door een delier of andere comorbiditeit. 
Er moeten minstens vijf cognitieve domeinen, waarvan bekend is dat ze aangetast 
kunnen worden door hiv, worden onderzocht om HAND te kunnen classificeren (dat 
wil zeggen executieve functies, aandacht/werkgeheugen, taal, snelheid van informatie-
verwerking, motorisch functioneren, geheugen). Deze cognitieve domeinen dienen 
onderzocht te worden met gevalideerde neuropsychologische tests die vervolgens 
geïnterpreteerd worden aan de hand van normscores. Volgens de criteria is het echter 
ook toegestaan om gestandaardiseerde korte cognitieve screeningsinstrumenten te 
gebruiken als een uitgebreider neuropsychologisch onderzoek niet mogelijk is.
 Naast neuropsychologische tests en cognitieve screeningsinstrumenten kan 
ook het in beeld brengen van afwijkingen in de hersenen belangrijk zijn om inzicht te 
verkrijgen in de invloed van hiv op de hersenen zelf en dit te kunnen relateren aan het 
cognitief functioneren. Corticale atrofie en wittestofafwijkingen zijn de twee meest 
voorkomende afwijkingen bij hiv-patiënten bij groepsonderzoek met magnetische 
resonantiebeeldvorming (magnetic resonance imaging of MRI). Vergeleken met een 
hiv-negatieve vergelijkingsgroep worden bij hiv-patiënten soms een kleinere 
amygdala,  nucleus caudatus, thalamus, hippocampus en cingulate cortex gevonden. 
Naast het in kaart brengen van de volumes van hersenstructuren kan ook de hersen-
activiteit worden gemeten, zonder dat de persoon een taak uitvoert. Dit kan middels 
resting-state functionele MRI (fMRI) gedaan worden. De hersenen bestaan uit 
verschillende netwerken die met elkaar verbonden zijn en geactiveerd worden, ook 
als iemand geen specifieke taak uitvoert. Met fMRI kan worden gekeken naar 
patronen van hersenactiviteit in deze netwerken. Dit wordt functionele connectiviteit 
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genoemd. Met deze techniek zijn afwijkingen gevonden bij hiv-patiënten in 
verschillende netwerken. Het was tot nu toe echter onbekend hoe en in welke mate 
afwijkingen in functionele connectiviteit bij hiv-patiënten samenhingen met cognitieve 
achteruitgang over tijd. 
 Naast deze objectieve maten is het ook van belang om de subjectieve ervaringen 
van hiv-patiënten te onderzoeken. Psychologische- en cognitieve klachten kunnen 
de kwaliteit van leven en het functioneren op het werk en in sociale situaties 
beïnvloeden. Aangezien verminderd psychisch welbevinden ook kan samenhangen 
met cognitieve klachten of zelfs stoornissen, is het belangrijk om deze ook bij 
hiv-patiënten te onderzoeken. 
 In dit proefschrift zijn het cognitief functioneren, hersenafwijkingen en het 
psychische welbevinden onderzocht in een Nederlandse groep hiv-patiënten die 
succesvol behandeld werden met cART. Deze groep is vergeleken met een 
vergelijkbare groep van gezonde, hiv-negatieve participanten.
 De eerste studie in dit proefschrift betreft een pilot-studie, ter voorbereiding op 
de daaropvolgende empirische studies. In hoofdstuk 2 werden de aard en de omvang 
van cognitieve tekorten onderzocht en gerelateerd aan psychisch welbevinden. 
Hierbij is – anders dan in eerdere studies – ook rekening gehouden met de mogelijkheid 
van onderpresteren, wat de symptoomvalidteit nadelig beïnvloedt. De participant-
groep bestond uit 30 hiv-patiënten, zowel behandelde als onbehandelde patiënten, 
en 30 gezonde hiv-negatieve controles van een vergelijkbare leeftijd, met een vergelijkbare 
geslachtsverdeling en een vergelijkbaar opleidingsniveau. Alleen patiënten zonder 
opportunistische infecties, maligniteiten, neurosyfilis en zwangerschap werden 
geïncludeerd. Zowel patiënten als gezonde deelnemers met een actuele alcohol- of 
drugsverslaving of een psychiatrische of neurologische voorgeschiedenis werden 
geëxcludeerd. In deze studie werd een uitgebreid neuropsychologisch onderzoek 
uitgevoerd. Dit bestond uit tests gericht op de cognitieve domeinen verbale 
vloeiendheid, snelheid van informatieverwerking, leren, geheugen, executieve functies, 
aandacht/werkgeheugen, motorische functies en visuoconstructie. Ook werd de Symptom 
Checklist (SCL-90-R) afgenomen. Dit is een vragenlijst waarmee onderzocht kan 
worden in welke mate iemand de afgelopen periode last had van verschillende 
psychische en/of lichamelijke klachten. Mogelijk onderpresteren werd gemeten 
met de verkorte versie van de Amsterdamse Korte Termijn Geheugentest (AKTG). 
De resultaten lieten zien dat slechts bij een klein aantal van zowel de patiënten als 
de controles er een indicatie was voor onderpresteren. Deze participanten zijn niet 
meegenomen in de verdere analyses. De groep hiv-patiënten liet een slechtere totale 
cognitieve prestatie zien in vergelijking met de gezonde controlegroep. Uit verdere 
analyses bleek dat dit effect met name toe te schrijven was aan een verminderde 
prestatie op het cognitieve domein werkgeheugen. Ook als de onbehandelde 
patiënten niet werden meegnomen in de analyses bleef dit effect bestaan. Er werden 
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geen verschillen gevonden in alle andere cognitieve domeinen. Daarnaast werd 
gevonden dat hiv-patiënten meer angst- en irritatiegerelateerde, depressieve-, cognitieve- 
en interpersoonlijke klachten rapporteerden dan de gezonde controles. De belangrijkste 
conclusie van deze studie was dat cognitieve tekorten en een lager niveau van 
psychologisch welbevinden mogelijk een probleem is bij hiv-patiënten, zelfs in het 
cART-tijdperk. Deze resultaten bevestigden de noodzaak voor vervolgonderzoek in 
een grotere groep participanten.
 Hoofdstukken 3 en 4 beschreven de baseline- en follow-up-studies waarin 
cognitief functioneren en psychologisch welbevinden werden onderzocht in een 
grote groep (n=95) hiv-patiënten die succesvol met cART behandeld werden. Deze 
groep werd vergeleken met een groep gezonde hiv-negatieve controles (n=55) die 
gematcht waren op leeftijd, geslacht en opleidingsniveau. Grotendeels dezelfde 
neuropsychologische testbatterij werd afgenomen als in de eerste pilot-studie. 
Het psychologisch welbevinden en kwaliteit van leven werd uitgebreider onderzocht, 
met naaste de eerder genoemde instrumenten ook de Hospital Anxiety and Depression 
Scale (HADS), de Cognitive Failures Questionnaire (CFQ) en de Medical Outcome 
Study-HIV Health Survey. Naast cognitief functioneren en welbevinden werd in het 
baseline-onderzoek ook witte- en grijzestofvolumes onderzocht door middel van 
MRI-scans bij zowel de patiënten als bij de controles. Er werd een verschil in prestatie 
gevonden tussen de patiënten en controles op de cognitieve domeinen snelheid van 
informatieverwerking en motorisch functioneren, waarbij de patiënten een lagere 
score behaalden. Hoewel statistisch significant, waren deze verschillen maar klein. 
Ook rapporteerden de patiënten een lager niveau van psychologisch welbevinden en 
een lagere kwaliteit van leven dan de controlegroep. Ook deze verschillen waren 
echter klein en individuele scores bleven vaak onder de klinische afkapwaarden. 
Er werden geen verschillen gevonden wat betreft angstige- en depressieve symptomen. 
Een zwakke maar significante correlatie werd gevonden tussen de zelfrapportage-
maten van psychologisch welbevinden en kwaliteit van leven enerzijds en de 
cognitieve domeinen motorisch functioneren en snelheid van informatieverwerking 
anderzijds. Een interessante bevinding was dat er geen relatie was tussen deze 
cognitieve domeinen en zelfrapportagevragen over het cognitief functioneren. Verder 
werden er kleine maar significante verschillen gevonden in de volumes van het totale 
brein en de thalamus tussen patiënten en controles, waarbij de volumes bij de 
patiënten kleiner waren. De belangrijkste conclusie van deze studie was dat de 
verschillen in cognitief functioneren, psychologisch welbevinden en hersenvolumes 
tussen patiënten en controles klein waren. Dit resultaat toont aan dat de hiv-infectie 
op zichzelf slechts een kleine impact heeft op het cognitief functioneren, psychologisch 
welbevinden en de hersenen bij hiv-patiënten die langdurig succesvol behandeld 
worden met cART.
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 Uit de eenjarige follow-up-studie bleek opnieuw dat de patiënten een slechtere 
score behaalden op het domein snelheid van informatieverwerking. Voor het domein 
verbale vloeiendheid werd op groepsniveau weliswaar geen verschil gevonden op de 
baseline, maar behaalden de patiënten een lagere score dan de controles bij de 
 follow-up-meting een jaar later. Voor het domein executief functioneren werd daaren - 
tegen geen verschil op groepsniveau gevonden op de follow-up, terwijl op de base-
linemeting door de patiënten een slechtere score behaald werd dan de controles. 
Naast groepsanalyses werden er individuele analyses uitgevoerd door middel van 
Reliable Change Indices (RCI’s) om betrouwbare cognitieve achteruitgang te meten 
op individueel niveau. Uit deze analyses bleek dat bij een kleine groep patiënten van 
13,4% sprake was van cognitieve achteruitgang op minstens één cognitief domein. 
De patiënten die cognitief achteruit gingen rapporteerden meer psychische klachten 
en waren vaker recreatieve drugsgebruikers. Deze patiënten verschilden in geen van 
de hiv-gerelateerde ziektevariabelen ten opzichte van de patiënten die niet cognitief 
achteruit gingen. We concludeerden uit deze studie dat de cognitieve achteruitgang 
in één jaar tijd gering is. We vonden namelijk slechts op één van de acht cognitieve 
domeinen achteruitgang op groepsniveau en op individueel niveau liet slechts een 
zeer kleine subgroep van de patiënten cognitieve achteruitgang zien.
 De validiteit van twee korte cognitieve screeningsinstrumenten, de Montreal 
Cognitive Assessment (MoCA) en de HIV Dementia Scale (HDS), bij het detecteren 
van cognitieve afwijkingen werd onderzocht in hoofdstuk 5. Cognitieve afwijkingen 
werden gemeten met dezelfde uitgebreide neuropsychologische testbatterij als in 
hoofdstukken 3 en 4 beschreven. Afwijkingen werden gedefinieerd aan de hand van 
twee welbekende classificatieprotocollen, namelijk de Frascati-criteria en de criteria 
voor Cognitive Impairment, No Dementia (CIND). De Frascati-criteria worden veel 
gebruikt in hiv-onderzoek, maar er zijn ook bezwaren geuit tegen deze criteria. Ze zouden 
namelijk te liberaal zijn in het classificeren van cognitieve afwijkingen, en daardoor 
resulteren in een te hoog aantal fout-positieve uitkomsten. Daarom gebruikten we in 
deze studie naast de Frascati-criteria ook de strengere CIND-criteria. Met de Frascati- 
criteria werd 41,1% van de hiv-patiënten geclassificeerd als cognitief afwijkend. Met 
de CIND-criteria lag dit aantal een stuk lager, namelijk 23,2%. Dit resultaat benadrukt 
het belang om betere criteria te gebruiken om hiv-gerelateerde cognitieve afwijkingen 
vast te stellen. Beide screeningsinstrumenten voorspelden cognitieve afwijkingen 
beter dan kansniveau. Het ene screening instrument was daarin echter niet beter dan 
het andere. Ook werden er voor beide instrumenten geen afkapwaardes gevonden 
die zowel een goede sensitiviteit als specificiteit hadden. Op basis van deze resultaten 
raden we het gebruik van beide instrumenten om hiv-gerelateerde cognitieve afwijkingen 
vast te stellen dan ook af.
 Hoofdstuk 6 beschreef een studie naar functionele connectiviteit gemeten met 
resting-state fMRI (rs-fMRI) tussen subcortale gebieden van de hersenen (basale 
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ganglia, hippocampus, amygdala en de thalamus). De resultaten werden geanalyseerd 
met een nieuw algoritme gebaseerd op een sensitieve Bayesiaanse methode. De sterkste 
correlaties werden gevonden tussen de overeenkomstige hersengebieden in de 
linker- en rechter hemisferen. Er werden geen verschillen gevonden in resting- state-
connectiviteit in de subcorticale gebieden tussen de hiv-patiënten en de gezonde 
controles. Geconcludeerd werd dat deze resultaten in lijn zijn met de bevindingen 
beschreven in hoofdstuk 3 van dit proefschrift en andere recente bevindingen die 
aantonen dat er kleine en soms zelfs geen cognitieve afwijkingen en neurale 
veranderingen te vinden zijn in hiv-patiënten die succesvol behandeld worden. 
 Tot slot werd in hoofdstuk 7 aandacht besteed aan de implicaties van boven - 
staande studies voor de klinische praktijk en werden er aanbevelingen gedaan voor 
toekomstig onderzoek. Ook bevat dit hoofdstuk de discussie van dit proefschrift 
waarbij de resultaten in een breder perspectief werden geplaatst. Concluderend kan 
gesteld worden dat de impact van een hiv-infectie an sich op het cognitief functioneren, 
het psychologisch welbevinden en de hersenen klein is bij patiënten die langdurig 
succesvol behandeld worden met cART. De verschillen op alle uitkomstmaten bleven 
daarbij vaak boven de klinische afkapwaarden. Dit is een voorzichtig positieve 
boodschap voor alle Nederlandse hiv-patiënten die succesvol behandeld worden.
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Abstract DGCN for Donders Series
Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), which 
was officially recognised as a national graduate school in 2009. The Graduate School 
covers training at both Master’s and PhD level and provides an excellent educational 
context fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students 
in biology, physics, psycholinguistics, psychology, behavioral science, medicine and 
related disciplines. Selective admission and assessment centers guarantee the 
enrolment of the best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, 
e.g. Stanford University, University of Oxford, University of Cambridge, UCL London, 
MPI Leipzig, Hanyang University in South Korea, NTNU Norway, University of Illinois, 
North Western University, Northeastern University in Boston, ETH Zürich, University 
of Vienna etc.. Positions outside academia spread among the following sectors: 
specialists in a medical environment, mainly in genetics, geriatrics, psychiatry and 
neurology. Specialists in a psychological environment, e.g. as specialist in neuro-
psychology, psychological diagnostics or therapy. Positions in higher education as 
coordinators or lecturers. A smaller percentage enters business as research consultants, 
analysts or head of research and development. Fewer graduates  stay in a research 
environment as lab coordinators, technical support or policy advisors. Upcoming 
possibilities are positions in the IT sector and management position in pharmaceutical 
industry. In general, the PhDs graduates almost invariably continue with high-quality 
positions that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit: 
http://www.ru.nl/donders/graduate-school/phd/
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